<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="P492 Corpus callosal myelin water fraction and transcallosal inhibition in" exact="multiple sclerosis" post="IM Vavasour 1, EY Zhao 2, MR Borich 3,"/>
 <result pre="fraction (MWF), a marker for central nervous system demyelination in" exact="multiple sclerosis" post="(MS). Transcallosal inhibition (TCI), elicited by transcranial magnetic stimulation"/>
 <result pre="musculature. Single pulses were delivered ipsilaterally to elicit a transient" exact="suppression" post="in the electromyographic activity of the forearm during a"/>
 <result pre="(50% max). The onset latency, duration and depth of this" exact="suppression" post="were used to quantify levels of TCI. Results: TCI"/>
 <result pre="tract pathology, such as traumatic spinal cord injury (SCI) and" exact="neuromyelitis optica" post="(NMO) with extensive spinal cord lesions, gave conflicting results."/>
 <result pre="(SCI and NMO), inflammatory tumour-like lesions (TLL) and relapsing remitting" exact="multiple sclerosis" post="(RRMS) with or without spinal cord lesions. Methods: Fifteen"/>
 <result pre="in RRMS. P494 Characteristic of orbit magnetic resonance imaging in" exact="neuromyelitis optica" post="and multiple sclerosis patients presenting with optic neuritis Y-M"/>
 <result pre="Characteristic of orbit magnetic resonance imaging in neuromyelitis optica and" exact="multiple sclerosis" post="patients presenting with optic neuritis Y-M Lim 1, KM"/>
 <result pre="imaging in neuromyelitis optica and multiple sclerosis patients presenting with" exact="optic neuritis" post="Y-M Lim 1, KM An 1, J Lee 1,"/>
 <result pre="Police Hospital, Neurology, Seoul, Korea, Republic of Background: Patients with" exact="neuromyelitis optica" post="(NMO) and multiple sclerosis (MS) both can present with"/>
 <result pre="Korea, Republic of Background: Patients with neuromyelitis optica (NMO) and" exact="multiple sclerosis" post="(MS) both can present with optic neuritis (ON). There"/>
 <result pre="optica (NMO) and multiple sclerosis (MS) both can present with" exact="optic neuritis" post="(ON). There have been several reports on neuroimaging findings"/>
 <result pre="NMO/NMOSD from MS. P495 High field spinal cord imaging in" exact="multiple sclerosis" post="at 7 Tesla S Pawate 1, A Dula 2,"/>
 <result pre="Amsterdam, Netherlands Background: Both spinal cord and brain atrophy in" exact="neuromyelitis optica" post="(NMO) was reported. However how is the relationship between"/>
 <result pre="with other MRI measurements and clinical disability, compared with well-matched" exact="multiple sclerosis" post="(MS) patients and healthy controls (HC). Methods: We recruited"/>
 <result pre="shift imaging as a sensitive measure of longitudinal changes in" exact="multiple sclerosis" post="lesions V Wiggermann 1,2, E Hernandez-Torres 2,3, IM Vavasour"/>
 <result pre="decrease in frequency at long-term follow up. P500 Distinction between" exact="neuromyelitis optica" post="and multiple sclerosis using multi-voxel pattern classification MA Sahraian"/>
 <result pre="at long-term follow up. P500 Distinction between neuromyelitis optica and" exact="multiple sclerosis" post="using multi-voxel pattern classification MA Sahraian 4, V Wottschel"/>
 <result pre="(NMO) is often the alternative diagnosis in patients misdiagnosed with" exact="multiple sclerosis" post="(MS), because patients with both diseases share some similarities."/>
 <result pre="magnetic resonance imaging (MRI) criteria to support the diagnosis of" exact="multiple sclerosis" post="(MS) are based on dissemination in time (DIT) and"/>
 <result pre="P502 A longitudinal study of spinal cord atrophy in progressive" exact="multiple sclerosis" post="D Plantone 1, H Kearney 1, MC Yiannakas 1,2,"/>
 <result pre="Spinal cord atrophy is strongly associated with physical disability in" exact="multiple sclerosis" post="(MS) and has previously been used as a secondary"/>
 <result pre="Clinical Translational Research Center, Buffalo, NY, United States Background: Although" exact="multiple sclerosis" post="(MS) was originally considered to be a disease affecting"/>
 <result pre="of GM pathology. P504 Microstructural white matter damage in fatigued" exact="multiple sclerosis" post="patients: a DTI-TBSS study A d’Ambrosio 1,2, G Caiazzo"/>
 <result pre="Neurology, St. Louis, MO, United States Background: For many years," exact="multiple sclerosis" post="(MS) has been considered as a &quot;white matter (WM)&quot;"/>
 <result pre="in clinical use. P506 Functional neuroimaging of inattentional blindness in" exact="multiple sclerosis" post="J Ellis 1, K Romero 1, M Theaudin 1,"/>
 <result pre="University, Tel Aviv, Israel Background: Diffusion-tensor imaging (DTI) studies in" exact="multiple sclerosis" post="(MS) reveal white matter (WM) injury with disease progression."/>
 <result pre="time. Objectives: To evaluate microstructural white matter damage in relapsing-remitting" exact="multiple sclerosis" post="(RRMS) as measured by brain DTI in patients with"/>
 <result pre="WM microstructure. P508 Regional cortical thickness in African Americans with" exact="multiple sclerosis" post="M Alkawaz 1, E Monohan 1, JS Perumal 1,"/>
 <result pre="P509 Can we really differentiate spinal cord ischemia from the" exact="myelitis" post="of neuromyelitis optica with MRI in the acute setting?"/>
 <result pre="we really differentiate spinal cord ischemia from the myelitis of" exact="neuromyelitis optica" post="with MRI in the acute setting? E Johnson 1,"/>
 <result pre="United States Background: Both spinal cord infarct and the acute" exact="myelitis" post="associated with Neuromyelitis Optica (NMO) have similar clinical presentations"/>
 <result pre="identify useful distinguishing imaging features for differentiating SCI from NMO" exact="myelitis" post="during an acute clinical presentation. Methods: We used a"/>
 <result pre="in all subjects. Results: The age at presentation for acute" exact="myelitis" post="did not differ between groups (mean 51 yrs, P&amp;gt;0.05),"/>
 <result pre="well as other brain metabolite concentrations, in patients with relapsing" exact="multiple sclerosis" post="(RMS) compared to healthy controls. Methods: 26 RMS subjects"/>
 <result pre="which until recently was considered to be a subtype of" exact="multiple sclerosis" post="(MS). NMO is characterized by episodes of inflammation and"/>
 <result pre="of inflammation and damage to astrocytes that can result in" exact="optic neuritis" post="and myelitis. Unlike MS, the immune attacks in NMO"/>
 <result pre="Resting state fMRI probed as predictor of fatigue symptoms in" exact="multiple sclerosis" post="PG Sämann 1, M Knop 2, S Nischwitz 2,"/>
 <result pre="brain. Objectives: To propose a new approach (SLF) to fill" exact="multiple sclerosis" post="(MS) lesions in T1-w images that overcomes some of"/>
 <result pre="perfusion weighted imaging - a marker of inflammatory activity in" exact="multiple sclerosis?" post="P Sowa 1,2, GO Nygaard 2,3, A Bjørnerud 4,5,"/>
 <result pre="P517 Cellular and microstructural changes due to iron deposition in" exact="multiple sclerosis" post="lesions Y Ge 1, H Sheng 1, S Chawla"/>
 <result pre="tool in detecting iron deposition in many neurological diseases including" exact="multiple sclerosis" post="(MS). Although several studies reported increased iron deposition in"/>
 <result pre="and warrant further investigation. P518 Imaging of brain perfusion in" exact="multiple sclerosis" post="and neurodegenerative disorders: association with endothelial factors. An interim"/>
 <result pre="episodic inflammation in focal lesions resulting in demyelination of axons," exact="neurodegeneration" post="and axonal loss. Conventional magnetic resonance (MR) outcomes correlate"/>
 <result pre="frequency shift imaging demonstrates that iron accumulation is rare in" exact="multiple sclerosis" post="lesions V Wiggermann 1,2, LE Lee 3, E Hernandez-Torres"/>
 <result pre="BC, Canada Background: One of the main radiological signs of" exact="multiple sclerosis" post="(MS) is the appearance of focal lesions due to"/>
 <result pre="MS lesions. P521 Characteristics of patients with MRI-only conversion to" exact="multiple sclerosis" post="after a clinically isolated syndrome WJ Brownlee 1, JK"/>
 <result pre="of these patients satisfy McDonald criteria for a diagnosis of" exact="multiple sclerosis" post="(MS) with MRI, but not clinical evidence of dissemination"/>
 <result pre="impairment in the long term. P522 Discriminative radiological features of" exact="multiple sclerosis" post="and neuromyelitis optica in Chinese patients S Cheng 1,"/>
 <result pre="long term. P522 Discriminative radiological features of multiple sclerosis and" exact="neuromyelitis optica" post="in Chinese patients S Cheng 1, R Li 1,"/>
 <result pre="Hospital, Hong Kong, Hong Kong Background: Multiple sclerosis (MS) and" exact="neuromyelitis optica" post="(NMO) are recognized to be clinically distinct entities which"/>
 <result pre="network (DMN) represent a potential biomarker for clinical disability in" exact="multiple sclerosis" post="(MS). Cortical areas part of the DMN are also"/>
 <result pre="Department, Barcelona, Spain Background: Some of the available treatments for" exact="multiple sclerosis" post="(MS) have demonstrated to improve the curve of brain"/>
 <result pre="brain tissue. Many studies have documented increased T1 associated with" exact="multiple sclerosis" post="(MS) disease progression in normal appearing white and gray"/>
 <result pre="other neurodegenerative diseases. P527 1-H MRSI in patients with relapsing" exact="multiple sclerosis" post="at 7 Tesla Y Li 1, BAC Cree 2,"/>
 <result pre="spectroscopic imaging has the potential to provide mechanistic insights in" exact="multiple sclerosis" post="(MS). With improved detection of myo-Inositol (mI), glutamate (Glu),"/>
 <result pre="lesion evolution. P528 Utilization of routine magnetic resonance imaging in" exact="multiple sclerosis" post="patient management S Cohan 1, C Chen 1, L"/>
 <result pre="MRI in therapeutic decision-making in clinically stable patients with relapsing" exact="multiple sclerosis" post="(RMS), treated with first-line DMT. Methods: A retrospective chart"/>
 <result pre="era of diminishing healthcare resources. P529 Basal ganglia iron in" exact="multiple sclerosis" post="patients measured with 7T quantitative susceptibility mapping (QSM) correlates"/>
 <result pre="Center, Radiology, Seattle, WA, United States Background: Brain atrophy in" exact="multiple sclerosis" post="(MS) occurs at a faster rate than the normal"/>
 <result pre="an association between depression and hippocampal atrophy in patients with" exact="multiple sclerosis" post="(MS). Objectives: Aim of this study was to investigate"/>
 <result pre="(DTI) and magnetization transfer imaging (MTI) are increasingly utilized in" exact="multiple sclerosis" post="(MS) clinical trials. The relationship between these MRI measures"/>
 <result pre="a mouse model of inflammatory cerebral demyelination. Methods: Experimental autoimmune" exact="encephalomyelitis" post="(EAE) was induced in C57BL/6 mice (n=12) using MOG"/>
 <result pre="use of imaging biomarkers in MS clinical development. P534 Automatic" exact="multiple sclerosis" post="brain lesion localisation and volumetry S Jain 1, D"/>
 <result pre="(MRI) are important criteria for diagnosis, follow-up and prognosis of" exact="multiple sclerosis." post="Quantitative values such as lesion volumetry are expected to"/>
 <result pre="prior knowledge that lesions appear hyperintense on FLAIR images. 20" exact="multiple sclerosis" post="patients participated in a study at VU University Medical"/>
 <result pre="Disruption of brain functional reorganization leads to disability progression in" exact="multiple sclerosis" post="A Faivre 1, E Robinet 1, C Rousseau 1,"/>
 <result pre="have demonstrated consistent reorganization of brain networks in patients with" exact="multiple sclerosis" post="(MS), with complex relationships with disability. Objectives: We aimed"/>
 <result pre="PSIR images improve detection and classification of cortical lesions in" exact="multiple sclerosis" post="and clinically isolated syndromes A Favaretto 1, D Poggiali"/>
 <result pre="Cortical gray matter lesions (CL) constitute a relevant aspect of" exact="multiple sclerosis" post="(MS) pathology. Studies based on double inversion recovery (DIR)"/>
 <result pre="Compensatory remapping of fMRI functional connectivity during resting state in" exact="multiple sclerosis" post="S-J Lin 1, A Liu 2, ZJ Wang 2,"/>
 <result pre="Altered functional connectivity appears to be a robust feature in" exact="multiple sclerosis" post="(MS). Compensatory mechanisms, whereby functional connectivity between brain regions"/>
 <result pre="robust alterations in fMRI connectivity patterns in patients with relapsing" exact="multiple sclerosis" post="(RMS) compared to age and gender matched healthy controls."/>
 <result pre="pathways. P539 Permeability of the blood-brain barrier predicts conversion from" exact="optic neuritis" post="to multiple sclerosis SP Cramer 1,2, HJ Simonsen 1,"/>
 <result pre="of the blood-brain barrier predicts conversion from optic neuritis to" exact="multiple sclerosis" post="SP Cramer 1,2, HJ Simonsen 1, JL Frederiksen 2,"/>
 <result pre="(BBB) in normal appearing white matter (NAWM) in patients with" exact="multiple sclerosis" post="(Cramer et al. 2013). 50% of patients with Optic"/>
 <result pre="conspicuity between two contrast-enhanced T1-weighted sequences in the detection of" exact="multiple sclerosis" post="lesions with 3.0T MRI F-X Aymerich 1, C Auger"/>
 <result pre="spin-echo (SE) is the sequence of choice to detect enhancing" exact="multiple sclerosis" post="(MS) lesions with 3.0T MRI. Objectives: The aim of"/>
 <result pre="inter-hemispheric functional connectivity is related to clinical measures of disabilityin" exact="multiple sclerosis" post="DA Boratyn 1, SA Tobyne 1, EC Klawiter 2,3"/>
 <result pre="in somatomotor and visual cortices in healthy controls (HC). In" exact="multiple sclerosis" post="(MS), studies have largely examined inter-hemispheric connectivity of a"/>
 <result pre="Central and peripheral alterations in glucose uptake in patients with" exact="multiple sclerosis" post="during treadmill walking JH Kindred 1, JR Hebert 2,"/>
 <result pre="Department of Statistics, Coventry, United Kingdom Background: The assessment of" exact="multiple sclerosis" post="(MS) is largely based on clinical scores and only"/>
 <result pre="are influenced by the degree of cervical spine involvement in" exact="multiple sclerosis" post="LH Hua 1, SL Donlon 2, MJ Sobhanian 3,"/>
 <result pre="as a marker for disease progression in patients with relapsing-remitting" exact="multiple sclerosis" post="using magnetic resonance spectroscopic imaging V Fleischer 1, R"/>
 <result pre="Germany Background: Magnetic resonance spectroscopic imaging (MRSI) in patients with" exact="multiple sclerosis" post="(MS) offers the possibility to detect metabolic alterations in"/>
 <result pre="with the progressive neurological disability. The relation between inflammation and" exact="neurodegeneration" post="is currently intensively debated and, at later stages of"/>
 <result pre="States Background: Vitamin D deficiency is a risk factor for" exact="multiple sclerosis" post="(MS). Low vitamin D levels are associated with increased"/>
 <result pre="D might play a role in grey matter atrophy and" exact="neurodegeneration" post="in MS. The lack of correlations in the RRMS"/>
 <result pre="examined evolution of iron deposition on susceptibility-weighted imaging (SWI) in" exact="multiple sclerosis" post="(MS) patients. Objectives: To explore whether treatment with glatiramer"/>
 <result pre="patients. P552 Cortical and subcortical volume dynamics in active relapsing-remitting" exact="multiple sclerosis" post="patients treated with in Fingolimod (Gilenya) A Achiron 1,2,"/>
 <result pre="Neuroradiology, Ramat Gan, Israel Background: Morphometric brain changes in relapsing-remitting" exact="multiple sclerosis" post="(RRMS) include alterations in the volume of subcortical regions,"/>
 <result pre="one year of treatment. P553 Perfusion and diffusion changes in" exact="multiple sclerosis" post="lesions and correlation with brain atrophy and clinical disability"/>
 <result pre="Detroit, MI, United States Background: Although the pathogenesis of the" exact="multiple sclerosis" post="(MS) is not yet fully understood, it has been"/>
 <result pre="connectivity is related to atrophy of the corpus callosum in" exact="multiple sclerosis" post="S Tobyne 1, D Boratyn 1, EC Klawiter 1"/>
 <result pre="(CC) is a hallmark feature of white matter pathology in" exact="multiple sclerosis" post="(MS). Degeneration of the CC is hypothesized to impair"/>
 <result pre="RRMS. P555 Imaging myelin pathology in the gray matter in" exact="multiple sclerosis" post="Y Wang 1, C Wu 1, J Zhu 1,"/>
 <result pre="Reserve University, Cleveland, OH, United States Background: Clinical disability in" exact="multiple sclerosis" post="(MS) is often associated with distinct myelin pathology in"/>
 <result pre="P556 Sex differences in brain glucose uptake in patients with" exact="multiple sclerosis" post="during walking JR Hebert 1, JH Kindred 2, M"/>
 <result pre="CD8+ T cells and CD19+ B cells isolated from relapsing/remitting" exact="multiple sclerosis" post="patients MC Graves 1, M Benton 2, R Lea"/>
 <result pre="lymphocytes has not been assessed. The development and progression of" exact="multiple sclerosis" post="result in part from the balance between effector and"/>
 <result pre="differentiation and is instrumental in prevention of autoimmune diseases and" exact="multiple sclerosis." post="We further demonstrated that 25-OHC prevented T R1 cell"/>
 <result pre="for Neurologic Diseases, Boston, MA, United States Background: Experimental autoimmune" exact="encephalomyelitis" post="(EAE) induced by myelin protein peptides serves as the"/>
 <result pre="cells. P563 Identification of a key role for complement in" exact="neurodegeneration" post="in multiple sclerosis I Huitinga 1, I Michailidou 2,"/>
 <result pre="Identification of a key role for complement in neurodegeneration in" exact="multiple sclerosis" post="I Huitinga 1, I Michailidou 2, M van Strien"/>
 <result pre="and axons is a main cause of clinical disability in" exact="multiple sclerosis" post="(MS) but the mechanisms responsible for neurodegeneration are largely"/>
 <result pre="disability in multiple sclerosis (MS) but the mechanisms responsible for" exact="neurodegeneration" post="are largely unknown. A number of studies suggest that"/>
 <result pre="recent identification of the association between complement genetic variants and" exact="neurodegeneration" post="in classical neurodegenerative diseases, led to our hypothesis that"/>
 <result pre="complement components and regulators in post-mortem brainstem tissue from progressive" exact="multiple sclerosis" post="donors, in relation to neuropathological changes, and compared the"/>
 <result pre="neurons, subsequent clinical disability and neuropathology in the experimental autoimmune" exact="encephalomyelitis" post="(EAE) model of MS. In addition, pharmacological inhibition of"/>
 <result pre="in MS grey matter and plays a key role in" exact="neurodegeneration" post="in models and man. P564 Intrathecal Epstein-Barr virus specific"/>
 <result pre="man. P564 Intrathecal Epstein-Barr virus specific CD8 T-cell responses in" exact="multiple sclerosis" post="patients are directed to lytic viral antigens GP van"/>
 <result pre="interferon-beta and inhibits IL-12 expression: a novel immunomodulatory mechanism in" exact="multiple sclerosis" post="LL Aung 1, V Bhise 1, S Dhib-Jalbut 1,"/>
 <result pre="of human Th17 subsets in healthy subjects and patients with" exact="multiple sclerosis" post="D Hu 1, N Pochet 1, R Cialic 1,"/>
 <result pre="Multiple Sclerosis (MS) is a chronic central nervous system (CNS)" exact="autoimmune disease" post="in which proinflammatory Th17 cells are increased. Recent studies"/>
 <result pre="the pathogenicity of the cells. P567 The immunological architecture of" exact="multiple sclerosis" post="and treatment J Dooley 1,2, I Pauwels 3, D"/>
 <result pre="importance of the adaptive immune system in the development of" exact="multiple sclerosis." post="However in-depth analysis of the role of the adaptive"/>
 <result pre="the adaptive immune system in the development and resolution of" exact="autoimmune disease" post="in human patients has proven to be difficult due"/>
 <result pre="have applied a systems immunology approach to the study of" exact="multiple sclerosis" post="(MS) and for comparison another autoimmune disorder, autoimmune thyroid"/>
 <result pre="multiple sclerosis (MS) and for comparison another autoimmune disorder, autoimmune" exact="thyroid disease" post="(AITD), to identify unique immunological signatures of disease and"/>
 <result pre="of 38 variables covering the adaptive immune system in 219" exact="autoimmune disease" post="patient samples (MS: N=164, AITD: N=55) and 36 healthy"/>
 <result pre="well as promoted CNS T cell immune modulation in the" exact="multiple sclerosis" post="(MS) model, experimental autoimmune encephalomyelitis (EAE) (Benkhoucha M. et"/>
 <result pre="immune modulation in the multiple sclerosis (MS) model, experimental autoimmune" exact="encephalomyelitis" post="(EAE) (Benkhoucha M. et al., PNAS, 2010). We showed"/>
 <result pre="Our results identify GILZ as a critical factor for effective" exact="suppression" post="of T-cell-mediated CNS inflammation by HGF via the induction"/>
 <result pre="of Pathology, Shanghai, China Background: Multiple sclerosis (MS) is an" exact="autoimmune disease" post="of the CNS characterized by a CD4+ Th1 lymphocyte-mediated"/>
 <result pre="by myelin oligodendrocyte glycoprotein (MOG 35-55) to induce experimental autoimmune" exact="encephalomyelitis" post="(EAE) and then given CGS21680 by i.p. daily. Neurological"/>
 <result pre="Autoreactive CD4 +T cells are important in the pathogenesis of" exact="multiple sclerosis" post="(MS). CD4 +T cells can be classified into six"/>
 <result pre="of early response to toll-like receptor 7 agonist stimulation in" exact="multiple sclerosis" post="patients MP Mycko 1, H Cwiklinska 1, M Cichalewska"/>
 <result pre="autoimmune demyelination. Methods: We studied function of pDCs in relapsing-remitting" exact="multiple sclerosis" post="(RRMS; n=32) patients and controls (n= 33) by analysis"/>
 <result pre="mechanisms of MS. P574 Neuroprotective effects of calcitriol in autoimmune" exact="optic neuritis" post="K-W Sühs 1, K Pars 1, SK Williams 2,"/>
 <result pre="form of vitamin D 3, in a rat model of" exact="optic neuritis," post="using myelin oligodendrocyte glycoprotein (MOG) induced experimental autoimmune encephalomyelitis"/>
 <result pre="optic neuritis, using myelin oligodendrocyte glycoprotein (MOG) induced experimental autoimmune" exact="encephalomyelitis" post="(EAE). Methods: RGCs were retrogradly labelled by stereotactical fluorogold"/>
 <result pre="P576 Immune cells in the diffusely abnormal white matter of" exact="multiple sclerosis" post="C Laule 1,2,3, V Pavlova 2, E Leung 2,"/>
 <result pre="useful for demonstrating areas of damage which can occur in" exact="multiple sclerosis" post="(MS) brain. Diffusely-abnormal white matter (DAWM) exhibits a signal"/>
 <result pre="P577 Interleukin-1β activates the apoptotic protein p53 to cause excitotoxic" exact="neurodegeneration" post="and disease progression in multiple sclerosis S Rossi 1,2,"/>
 <result pre="protein p53 to cause excitotoxic neurodegeneration and disease progression in" exact="multiple sclerosis" post="S Rossi 1,2, V Studer 1,2, C Motta 1,2,"/>
 <result pre="apoptotic pathways. Apoptosis and excitotoxcicity are proposed as determinants of" exact="neurodegeneration" post="in many neurological diseases and could be the link"/>
 <result pre="neurological diseases and could be the link between neuroinflammation and" exact="neurodegeneration" post="in multiple sclerosis (MS). Objectives: To investigate the role"/>
 <result pre="and could be the link between neuroinflammation and neurodegeneration in" exact="multiple sclerosis" post="(MS). Objectives: To investigate the role of the apoptotic"/>
 <result pre="damage was modulated by p53 genotype. Conclusions: Inflammatory synaptopathy and" exact="neurodegeneration" post="caused by IL-1β in RRMS patients involve the apoptotic"/>
 <result pre="to intrathecal antibodies in the cerebrospinal fluid of patients with" exact="multiple sclerosis" post="H Collins 1, D Gunaydin 1, K Tamanito 1,"/>
 <result pre="response are unknown. The risk of MS is increased after" exact="infectious mononucleosis," post="and MS patients have higher serum titers of EBV"/>
 <result pre="1 1Université de Montréal, CRCHUM, Montréal, QC, Canada Background: In" exact="multiple sclerosis" post="(MS), CD4 + T helper (TH) cells are of"/>
 <result pre="ephrin/Eph system in MS and its animal model, experimental autoimmune" exact="encephalomyelitis" post="(EAE), specifically in the pathogenicity and migration potential of"/>
 <result pre="Münster, Germany Background: CD8+ T cells are frequently found in" exact="multiple sclerosis" post="lesions, however their precise influence on disease pathology is"/>
 <result pre="T cells in C57/Bl6 mice and induced active experimental autoimmune" exact="encephalomyelitis" post="(EAE) by immunization with MOG 33-55 after a reconstitution"/>
 <result pre="leading to a selective enrichment of OT-1 in experimental autoimmune" exact="encephalomyelitis" post="lesions. However, the myelin-recognition of CD8+ T cells in"/>
 <result pre="a clinically significant manner. P583 Mucosal associated invariant T-cells from" exact="multiple sclerosis" post="patients are effector cells with increased activation and homing"/>
 <result pre="allow further characterization in MS lesions. P584 Metabolic syndrome and" exact="multiple sclerosis." post="Metformin and thioazolinediones activate different immunomodulatory pathways J Correale"/>
 <result pre="thioazolinediones on immune regulation in obese MS patients who developed" exact="metabolic syndrome" post="Methods: Twenty obese patients with diagnosis of relapsing remitting"/>
 <result pre="patients with diagnosis of relapsing remitting MS, who also developed" exact="metabolic syndrome," post="were studied. Fourteen patients received metformin and 6 patients"/>
 <result pre="P585 Amino acid catabolism is altered in immune cells from" exact="multiple sclerosis" post="patients J Correale 1, MF Farez 1 1Institute for"/>
 <result pre="preventing autoimmunity, whereas increased AA catalytic activity may reinforce immune" exact="suppression" post="promoting pathogen persistence and chronic infection. Objectives: To evaluate"/>
 <result pre="in the therapeutic effect of glatiramer acetate in experimental autoimmune" exact="encephalomyelitis" post="R Aharoni 1, T Feferman 1, DD Bar Lev"/>
 <result pre="Glatiramer acetate (GA), a therapeutic agent for the treatment of" exact="multiple sclerosis" post="(MS), induces a broad immunomodulatory effect on various subsets"/>
 <result pre="the therapeutic activity of GA in the animal model of" exact="multiple sclerosis" post="- experimental autoimmune encephalomyelitis (EAE). Methods: Tregs were identified"/>
 <result pre="in the animal model of multiple sclerosis - experimental autoimmune" exact="encephalomyelitis" post="(EAE). Methods: Tregs were identified immunohistochemically in the CNS"/>
 <result pre="was tested in Foxp3GFPLuciDTR-4 transgenic mice, in which Tregs express" exact="diphtheria" post="toxin (DT) receptor, thus facilitating their selective depletion by"/>
 <result pre="in leukocytes in active lesions in MS and experimental autoimmune" exact="encephalomyelitis" post="(EAE) (Brain 136:1760, 2013). Furthermore, anti-EMMPRIN antibodies reduced the"/>
 <result pre="the animal model of Multiple Sclerosis (MS), i.e. experimental autoimmune" exact="encephalomyelitis" post="(EAE). Methods: We evaluated the effects of genetic ablation"/>
 <result pre="Tc17 and mucosal-associated invariant T cells in treated and untreated" exact="multiple sclerosis" post="patients L Negrotto 1, E Cantó 1, M Tintoré"/>
 <result pre="Spain Background: Th17 cells are important in the immunopathogenesis of" exact="multiple sclerosis" post="(MS). However, IL-17 production is not limited to CD4+"/>
 <result pre="of these therapies in MS. P590 Altered glycosylation patterns during" exact="multiple sclerosis" post="generate neo-autoantigens D Lefranc 1, B Oxombre 1, M"/>
 <result pre="of myeloid dendritic cells in peripheral blood of patients with" exact="multiple sclerosis" post="B Wildemann 1, A Schwarz 1, M Korporal-Kuhnke 1,"/>
 <result pre="the impaired development of regulatory T cells in patients with" exact="multiple sclerosis." post="P593 c-Myc activity in T-cells is critical for autoimmune"/>
 <result pre="copper. P595 Principal component analysis allows to cluster patients with" exact="multiple sclerosis" post="on the basis of different subsets of CD8+ and"/>
 <result pre="vary during autoimmune diseases. Increased serum concentration of IL-18 in" exact="multiple sclerosis" post="(MS) was previously shown. Objectives: to evaluate the level"/>
 <result pre="role of endogenous interferon-beta in the pathogenesis of relapsing remitting" exact="multiple sclerosis" post="X Zhang 1, Y Tao 1, S Markovic-Plese 1"/>
 <result pre="role of endogenous IFNb in the pathogenesis of relapsing remitting" exact="multiple sclerosis" post="(RRMS). Objectives: To investigate the role of endogenous IFNb"/>
 <result pre="(CNS) in the animal model of MS, i.e. experimental autoimmune" exact="encephalomyelitis" post="(EAE). Objectives: As the influence of NaCl on macrophages"/>
 <result pre="P599 Suppression of IL-10 production by calcitriol in patients with" exact="multiple sclerosis" post="M Niino 1, T Fukazawa 2, Y Miyazaki 3,"/>
 <result pre="Medical Center, Department of Neurology, Sapporo, Japan Background: Risk for" exact="multiple sclerosis" post="(MS) was found to decrease significantly with increasing serum"/>
 <result pre="Disability Status Scale (EDSS) scores, which means that stronger calcitriol-dependent" exact="suppression" post="of IL-10 was associated with higher EDSS score. Conclusions:"/>
 <result pre="brand Copaxone® (glatiramer acetate injection) in an animal model of" exact="multiple sclerosis" post="C Honan 1, TC Ganguly 1, I Fier 1,"/>
 <result pre="a generic version of Copaxone® for the treatment of relapsing-remitting" exact="multiple sclerosis" post="(RRMS) and is under FDA review. Equivalence between M356"/>
 <result pre="and Copaxone® by using several variants of the experimental autoimmune" exact="encephalomyelitis" post="(EAE) model, a longstanding and widely-used model of MS."/>
 <result pre="of Th1 cells, Th2 cells or macrophage/monocytes (M/M1). Experimental allergic" exact="encephalomyelitis" post="(EAE) was induced in mice by immunization with myelin-oligodendrocyte"/>
 <result pre="and spinal cords of mice with EAE, a model of" exact="multiple sclerosis" post="(MS). In glial cultures, FAT10 message was upregulated 600-fold"/>
 <result pre="treatment on lymphocyte subpopulations and S1P-dependent migration in patients with" exact="multiple sclerosis" post="T Hottenrott 1, H Sic 2, H Eibel 2,"/>
 <result pre="in all types of immune response including autoimmune diseases like" exact="multiple sclerosis" post="(MS). Lymphocyte egress from lymphoid tissue into the blood"/>
 <result pre="and fingolimod (FTY) are two efficacious treatment options in relapsing-remitting" exact="multiple sclerosis" post="(MS). NZB blocks alpha-4-associated extravasation whereas the main effector"/>
 <result pre="candidates involved in immunomodulatory processes in therapy and pathomechanism of" exact="multiple sclerosis" post="MJ Knop 1, S Nischwitz 2, H Faber 1,"/>
 <result pre="the expression of Th17-related genes on circulating CD4+ T-cells after" exact="multiple sclerosis" post="relapse C de Andres 1,2, MI Garcia 2, A"/>
 <result pre="T cell population in the Central Nervous System (CNS) in" exact="multiple sclerosis" post="(MS) lesions. However, no Th17 biomarkers have been consistently"/>
 <result pre="P606 Using social media for large-scale recruitment in a prospective" exact="multiple sclerosis" post="(MS) inception cohort: the genes and environment in MS"/>
 <result pre="global analysis of the use of social media to discuss" exact="multiple sclerosis" post="J Pakpoor 1, S Nyein 2, G Disanto 3,"/>
 <result pre="sites than any other type of site. Individuals affected by" exact="multiple sclerosis" post="(MS) and MS related organisations use social media to"/>
 <result pre="episodes or accumulate clinically silent MRI lesions, raising concern for" exact="multiple sclerosis" post="(MS) or neuromyelitis optica (NMO). As treatments differ, it"/>
 <result pre="silent MRI lesions, raising concern for multiple sclerosis (MS) or" exact="neuromyelitis optica" post="(NMO). As treatments differ, it is critical to distinguish"/>
 <result pre="implementing a blog, as a tool for better interaction between" exact="multiple sclerosis" post="patients and their doctors JD Steinberg 1, MC Curbelo"/>
 <result pre="and reviews. Surveys: physical/work or therapy access, sleep diseases, nutrition/dietary," exact="sexual dysfunction." post="The blog is fully in Spanish with Google translator."/>
 <result pre="modified by Candida kefyr reduces the susceptibility to experimental autoimmune" exact="encephalomyelitis" post="K Takata 1, T Tomita 2, T Koda 1,"/>
 <result pre="to examine the effects of dietary yeast on experimental autoimmune" exact="encephalomyelitis" post="(EAE). Methods: We chose 11 kinds of yeast which"/>
 <result pre="and immune- mediated CNS demyelination has shed light on human" exact="multiple sclerosis" post="etiology and clinical utilization of microbiota products. We have"/>
 <result pre="gut symbiont strain Bacteroides fragilis, protects against murine experimental autoimmune" exact="encephalomyelitis" post="(EAE) via TLR2 both prophylactically and therapeutically. TLR2 signaling"/>
 <result pre="both prophylactically and therapeutically. TLR2 signaling is critical for PSA-mediated" exact="suppression" post="of CNS inflammation and anatomically localized expansion of CD39"/>
 <result pre="P616 Gut microbiome is linked to immune cell phenotype in" exact="multiple sclerosis" post="R Gandhi 1, FV Glehn 1, MA Mazzola 1,"/>
 <result pre="derived from the gut microbiome in the treatment of human" exact="multiple sclerosis" post="(MS). P618 The MS Microbiome Consortium (MSMC): an academic"/>
 <result pre="with development or severity of Crohn’s disease, type I diabetes," exact="obesity" post="and autism. Objectives: To develop a multi-Center academic consortium"/>
 <result pre="P620 Expression profiles of inflammation associated microRNAs in astrocytes from" exact="multiple sclerosis" post="lesions VTS Rao 1, SC Fuh 1, CS Moore"/>
 <result pre="of new treatment paradigms to repair myelin in patients with" exact="multiple sclerosis" post="(MS). Agents which can promote oligodendrocyte precursor cell (OPC)"/>
 <result pre="of KIR4.1 in glia cells affects binding of autoantibodies in" exact="multiple sclerosis" post="R Srivastava 1, SR Kalluri 1, Y Schäfer 1,"/>
 <result pre="(KIR4.1) specific serum antibodies were reported in a sub-population of" exact="multiple sclerosis" post="(MS) patients. KIR4.1 is a glycosylated channel protein expressed"/>
 <result pre="Oligodendrocyte injury and inflammatory demyelination are important pathological abnormalities of" exact="multiple sclerosis" post="(MS) as well as in its animal model, the"/>
 <result pre="as well as in its animal model, the experimental autoimmune" exact="encephalomyelitis" post="(EAE). Emerging evidence over the last decade suggests that"/>
 <result pre="methylation sensitive PCR. Further, in-vitro studies have shown that human" exact="oligodendroglioma" post="(HOG) cells treated with cytokines caused cell death. We"/>
 <result pre="States Background: Excessive extracellular matrix (ECM) deposition in active demyelinating" exact="multiple sclerosis" post="(MS) lesions may impede axonal regeneration and can modify"/>
 <result pre="Molecular Science, Melbourne, Australia Background: Evidence from the experimental autoimmune" exact="encephalomyelitis" post="(EAE) model reveals a nonimmunological effect of the sphingosine-1"/>
 <result pre="treatment for various autoimmune conditions, treatment trials of IVIG for" exact="multiple sclerosis," post="using varying doses of IVIG, yielded controversial results. Objectives:"/>
 <result pre="entities. P632 Plasmablasts as AQP4-Ab producers in the pathogenesis of" exact="neuromyelitis optica" post="N Chihara 1,2,3, T Aranami 1,4, S Oki 1,"/>
 <result pre="of the central nervous system characterized by recurrent attacks of" exact="optic neuritis" post="and myelitis. Although the probable autoantigen aquaporin-4 (AQP4) is"/>
 <result pre="blood of healthy subjects or patients with NMO who received" exact="influenza" post="vaccination. The frequency of plasmablasts in a portion of"/>
 <result pre="in a portion of patients with NMO who received H1N1" exact="influenza" post="vaccination were elevated from the baseline for more than"/>
 <result pre="to target PBs and their migration. P633 Neuropsychiatric features of" exact="neuromyelitis optica" post="P Moore 1, A Methley 1, C Pollard 1,"/>
 <result pre="-1.5SD). 31.3% of participants met diagnostic criteria for a current" exact="anxiety disorder" post="and 16.7% for current depression. Lifetime prevalence of depression"/>
 <result pre="including age, disease duration, EDSS, or presence of depression or" exact="anxiety disorder." post="Conclusions: Evidence of at least mild impairment in cognitive"/>
 <result pre="therapy. P635 HLA class 11 alleles and environmental associations with" exact="neuromyelitis optica" post="in Indian population L Pandit 1, C Malli 1,"/>
 <result pre="is unclear whether there are genetic and environmental associations with" exact="neuromyelitis optica" post="(NMO) particularly in Indian population. Objectives: To determine HLA"/>
 <result pre="They included NMO diagnosed by Wingerchuck 2006 criteria (61), recurrent" exact="myelitis" post="with long cord lesions (11), recurrent optic neuritis (20)"/>
 <result pre="criteria (61), recurrent myelitis with long cord lesions (11), recurrent" exact="optic neuritis" post="(20) and sero positive recurrent tumefactive demyelination (1). DRB1&amp;amp;"/>
 <result pre="CD56 high NK cells and activated Treg-cells in patient with" exact="neuromyelitis optica" post="after treatment with anti-IL-6R antibody tocilizumab T Matsuoka 1,"/>
 <result pre="Medicine, Immunology, Tokyo, Japan Background: Neuromyelitis optica (NMO) is an" exact="autoimmune disease" post="of the central nervous system, accompanying elevation of pathogenic"/>
 <result pre="Evaluation of treatment response to plasmapheresis in acute exacerbations of" exact="neuromyelitis optica" post="GES Linhares 1, SLA Pereira 1, FMH Jorge 1,"/>
 <result pre="Paulo, Neurology, São Paulo, Brazil Background: Neuromyelitis optica is an" exact="autoimmune disease" post="of the central nervous system that presents predominantly with"/>
 <result pre="disease of the central nervous system that presents predominantly with" exact="optic neuritis" post="(ON) and myelitis. The association of the IgG class"/>
 <result pre="cord atrophy and 3rd. ventricle widening to clinical disability in" exact="neuromyelitis optica" post="R Schneider 1, B Bellenberg 2, F Weiler 3,"/>
 <result pre="Bremen, Germany Background: Neuromyelitis optica (NMO) can present similarly to" exact="multiple sclerosis" post="(MS) and involvement of the cervical cord is common"/>
 <result pre="the pathologic processes in NMO patients. P639 Neuromyelitis optica and" exact="neuromyelitis optica" post="spectrum disorder patients in Turkish cohort: demographic, clinical, laboratory"/>
 <result pre="as follows: Classical NMO, Single or recurrent attacks of transverse" exact="myelitis" post="with longitudinally extending spinal cord lesions (LETM), Recurrent optic"/>
 <result pre="transverse myelitis with longitudinally extending spinal cord lesions (LETM), Recurrent" exact="optic neuritis" post="(ON) with normal brain MRI or cranial MRI lesions"/>
 <result pre="normal brain MRI or cranial MRI lesions not compatible with" exact="multiple sclerosis" post="(MS), Optico-spinal MS (OSMS), ON or TM accompanying systemic"/>
 <result pre="the LETM group with respect to classical NMO and recurrent" exact="optic neuritis" post="(0.70±1.73 vs 0.17±0.34 and 0.08±0.12). The mean EDSS and"/>
 <result pre="the more severe disability in NMO/NMOSD patients presenting with transverse" exact="myelitis" post="and late onset subgroups. P640 Therapy of neuromyelitis optica"/>
 <result pre="with transverse myelitis and late onset subgroups. P640 Therapy of" exact="neuromyelitis optica" post="exacerbations: a retrospective evaluation of 840 episodes with 1168"/>
 <result pre="(NMOSD) typically take a relapsing disease course. In comparison to" exact="multiple sclerosis," post="exacerbations are often more severe, respond less to therapy"/>
 <result pre="rate was 1.06 (95% CI 0.96-1.12). 150 patients had ≥1" exact="optic neuritis" post="(ON) and 179 patients had ≥1 myelitis (MY). Episodes"/>
 <result pre="had ≥1 optic neuritis (ON) and 179 patients had ≥1" exact="myelitis" post="(MY). Episodes of isolated MY (59%) were more frequent"/>
 <result pre="Clinical and radiological profiles of anterior visual pathway involvement in" exact="neuromyelitis optica" post="I Kawachi 1, A Yokoseki 1, E Saji 1,"/>
 <result pre="pathway is a frequent site of injury, as shown by" exact="optic neuritis" post="(ON) during the course of neuromyelitis optica (NMO); however,"/>
 <result pre="as shown by optic neuritis (ON) during the course of" exact="neuromyelitis optica" post="(NMO); however, the details of pathomechanism in ON of"/>
 <result pre="that in NMOsd spinal cords. P642 Factor H autoantibodies in" exact="neuromyelitis optica" post="B Uzonyi 1, M Jozsi 1, Z Illes 2,3"/>
 <result pre="P643 Retrospective review of optimal treatment for acute relapses in" exact="neuromyelitis optica" post="H Abboud 1, M Mealy 2, S Sasidharan 2,"/>
 <result pre="Medical Center, Neurology, Baltimore, MD, United States Background: Patients with" exact="neuromyelitis optica" post="(NMO) are known to suffer from severe relapses that"/>
 <result pre="IVMP + PLEX in the treatment of acute relapses in" exact="neuromyelitis optica" post="(NMO). Methods: We conducted a retrospective review of 85"/>
 <result pre="with confirmed acute relapses of transverse myelitis, brainstem lesions and/or" exact="optic neuritis" post="treated with either high dose IVMP alone versus high"/>
 <result pre="is insufficient. P644 Pathological study of tumefactive brain lesions in" exact="neuromyelitis optica" post="Y Chang 1, W Qiu 1, B Zhang 1,"/>
 <result pre="may benefit the tumefactive brain lesion patients. P645 Is late-onset" exact="neuromyelitis optica" post="spectrum disorder associated with a worse outcome? H-J Cho"/>
 <result pre="aquaporin-4 (AQP4-ab) has been able to broaden this disease category;" exact="neuromyelitis optica" post="spectrum disorders (NMOSD). Recent studies suggested that the age"/>
 <result pre="needed. P646 Presence of HLA DR10 in Mexican patients with" exact="neuromyelitis optica" post="(Devic’s disease) J Flores 1, V Rivas 1, Y"/>
 <result pre="are attended for other diagnoses no including MS or another" exact="autoimmune disease." post="The samples in the laboratory following standardized procedures. The"/>
 <result pre="allele has been described in other autoimmune diseases such as" exact="rheumatoid arthritis" post="and it seems to be protective for MS in"/>
 <result pre="has been described in other autoimmune diseases such as rheumatoid" exact="arthritis" post="and it seems to be protective for MS in"/>
 <result pre="DRB1*15. P647 The plasma antiaquaporin antibodies and the outcome of" exact="myelitis" post="in neuromyelitis optica and neuromyelitis optica spectrum disorders: any"/>
 <result pre="The plasma antiaquaporin antibodies and the outcome of myelitis in" exact="neuromyelitis optica" post="and neuromyelitis optica spectrum disorders: any relationship? E Idiman"/>
 <result pre="antibodies and the outcome of myelitis in neuromyelitis optica and" exact="neuromyelitis optica" post="spectrum disorders: any relationship? E Idiman 1, F Idiman"/>
 <result pre="3Dokuz Eylul University, Oncology, Izmir, Turkey Background: Some patients with" exact="neuromyelitis optica" post="(NMO) and NMO spectrum disorders (NMOSD) have similar clinical"/>
 <result pre="AQP4 antibody has a relationship with the prognosis of transverse" exact="myelitis" post="in terms of motor disability. Methods: Sera of 34"/>
 <result pre="patients with NMO (n=27) and NMOSD with isolated or recurrent" exact="myelitis" post="(n=7) were all investigated for the presence of AQP4"/>
 <result pre="antibody-positive patients show significantly older disease onset. The outcome of" exact="myelitis" post="in terms of motor disability was similar in both"/>
 <result pre="anti-AQP4 antibody-positive and negative patients. P648 Autoantibodies in patients with" exact="neuromyelitis optica" post="WLCJ Pereira 1, AP Kallaur 1, SR Oliveira 1,"/>
 <result pre="2 years, p=0.0240). Although patients presented others autoimmune diseases (systemic" exact="lupus erythematosus," post="systemic sclerosis, juvenile rheumatoid arthritis, hypothyroidism, hyperthyroidism and Raynaud’s"/>
 <result pre="presented others autoimmune diseases (systemic lupus erythematosus, systemic sclerosis, juvenile" exact="rheumatoid arthritis," post="hypothyroidism, hyperthyroidism and Raynaud’s phenomenon), no statistically significant differences"/>
 <result pre="diseases (systemic lupus erythematosus, systemic sclerosis, juvenile rheumatoid arthritis, hypothyroidism," exact="hyperthyroidism" post="and Raynaud’s phenomenon), no statistically significant differences were found"/>
 <result pre="Cheshire, CT, United States Background: Due to the rarity of" exact="neuromyelitis optica" post="(NMO) the prognosis on and off treatment is unclear."/>
 <result pre="and 13 mixed race /other. Only 3.6% had both transverse" exact="myelitis" post="(TM) and optic neuritis at onset. The median time"/>
 <result pre="race /other. Only 3.6% had both transverse myelitis (TM) and" exact="optic neuritis" post="at onset. The median time from onset to diagnosis"/>
 <result pre="age and attack type. P650 Magnetic resonance imaging features of" exact="optic neuritis" post="distinguishing neuromyelitis optica from multiple sclerosis HY Shin 1,"/>
 <result pre="type. P650 Magnetic resonance imaging features of optic neuritis distinguishing" exact="neuromyelitis optica" post="from multiple sclerosis HY Shin 1, NY Shin 2,"/>
 <result pre="resonance imaging features of optic neuritis distinguishing neuromyelitis optica from" exact="multiple sclerosis" post="HY Shin 1, NY Shin 2, M Park 2,"/>
 <result pre="Background: Optic neuritis (ON) may be the initial manifestations of" exact="multiple sclerosis" post="(MS) and neuromyelitis optic (NMO). Differential diagnosis between these"/>
 <result pre="ON. P651 Involvement of cerebral cortex in anti-aquaporin-4 antibody seropositive" exact="neuromyelitis optica" post="spectrum disorder patients SY Kim 1, W Kim 1,"/>
 <result pre="characteristic locations and configurations are helpful in the diagnosis of" exact="neuromyelitis optica" post="spectrum disorder (NMOSD). It was previously reported that cortical"/>
 <result pre="not found in patients with NMO, which was contrast to" exact="multiple sclerosis" post="(MS). Objectives: We aimed to determine whether involvement of"/>
 <result pre="symptom. 43.5% were not affected by Myelitis. 50% had Cervical" exact="myelitis" post="and 6.5% both cervical and thoracic myelitis. 23.9% had"/>
 <result pre="sensitivity of these laboratory tests. P653 An unusual case of" exact="neurofibromatosis" post="type 1, high titer antinuclear autoantibodies and neuromyelitis optica"/>
 <result pre="case of neurofibromatosis type 1, high titer antinuclear autoantibodies and" exact="neuromyelitis optica" post="Y Jin 1, D Segal 1, M Hillen 1"/>
 <result pre="been described. There are 5 case reports of NF1 with" exact="systemic lupus erythematosus" post="(SLE) and 6 case reports of NF1 with multiple"/>
 <result pre="described. There are 5 case reports of NF1 with systemic" exact="lupus erythematosus" post="(SLE) and 6 case reports of NF1 with multiple"/>
 <result pre="lupus erythematosus (SLE) and 6 case reports of NF1 with" exact="multiple sclerosis" post="in the medical literature up-to-date. Neuromyelitis optica (NMO) spectrum"/>
 <result pre="normal brain, abnormal T2 hyperintensity from T2-T6, as seen in" exact="myelitis" post="and L3-L5 root lesions which were proven to be"/>
 <result pre="gait improved after intravenous corticosteroid treatment. A diagnosis of autoimmune" exact="myelitis" post="was made. Patient was treated with oral steroids and"/>
 <result pre="or are coincidental needs further study. P654 Neuromyelitis optica and" exact="neuromyelitis optica" post="spectrum disorders: the evaluation of 86 patients followed by"/>
 <result pre="spectrum disorders (NMOSD) are relatively rare disorders when compared to" exact="multiple sclerosis" post="(MS). Objectives: We aimed to evaluate clinical characteristics and"/>
 <result pre="at our MS unit; 24 had NMO, 42 had recurrent" exact="optic neuritis" post="(RON); and 20 had longitudinally extensive transverse myelitis (LETM)."/>
 <result pre="recurrent optic neuritis (RON); and 20 had longitudinally extensive transverse" exact="myelitis" post="(LETM). The mean age of the patients was 40.1±14.1"/>
 <result pre="diseases may have neurological side-effects. Among them, few cases of" exact="optic neuritis" post="(ON) have been reported whatever anti-TNFa category. Objectives: The"/>
 <result pre="imaging in acute optic neuritis: a new potential biomarker for" exact="multiple sclerosis" post="RC Sergott 1, ML Moster 2, E Affel 3"/>
 <result pre="investigate the potential role for MLCI in patients with acute" exact="optic neuritis." post="Methods: We investigated 15 patients with acute optic neuritis"/>
 <result pre="acute optic neuritis. Methods: We investigated 15 patients with acute" exact="optic neuritis" post="at the time of their presentation and 3 months"/>
 <result pre="3 months after their initial visual symptoms. The event of" exact="optic neuritis" post="was the first clinical demyelinating event in 8 patients"/>
 <result pre="with RRMS. Results: In 10 of 15 patients with acute" exact="optic neuritis," post="MCLI demonstrated hyper-reflective zones encircling the fovea and macular"/>
 <result pre="monochromatic fundus photography. P657 White matter damage is associated with" exact="optic neuritis" post="related retinal nerve fiber and ganglion cell loss in"/>
 <result pre="neuritis related retinal nerve fiber and ganglion cell loss in" exact="neuromyelitis optica" post="spectrum disorders F Pache 1,2, H Zimmermann 1, S"/>
 <result pre="Neuromyelitis optica (NMO) is an autoimmune CNS disease characterized by" exact="optic neuritis" post="(ON) and myelitis. Attacks can be devastating, especially damage"/>
 <result pre="devastating, especially damage by ON is more severe than in" exact="multiple sclerosis." post="Previous studies reported retinal nerve fiber layer thinning in"/>
 <result pre="biomarker of disease and repair in a mouse model of" exact="multiple sclerosis" post="P Kim 1, A Khalaj 2, M Syed 2,"/>
 <result pre="is integral to developing treatments for neurodegenerative diseases such as" exact="multiple sclerosis" post="(MS). Optic neuritis (ON) is a common acute manifestation"/>
 <result pre="a common acute manifestation of MS onset; similarly, experimental autoimmune" exact="encephalomyelitis" post="(EAE) mice, a rodent model of MS, exhibit ON."/>
 <result pre="Retrograde axonal and neuronal degeneration of the retina in acute" exact="optic neuritis" post="EH Martínez-Lapiscina 1, I Gabilondo 1, E Fraga-Pumar 1,"/>
 <result pre="detailed description of the diffusion of retinal damage in acute" exact="optic neuritis" post="(ON) and its correlation with visual disability is relevant"/>
 <result pre="participants and 45% of non-fatigued participants had a history of" exact="optic neuritis" post="(ON). Ninety five percent and 5% of participants in"/>
 <result pre="Retinal structural injury is worse in African-Americans than Caucasians with" exact="multiple sclerosis" post="J Chorostecki 1, F Bao 1, G Bao 1,"/>
 <result pre="and macular atrophy than CAU-MS. In patients without history of" exact="optic neuritis," post="our results extend previous observations of greater irreversible tissue"/>
 <result pre="100 Hue testing is tightly associated with retinal thinning in" exact="multiple sclerosis" post="EE Longbrake 1, S Lancia 1, N Tutlam 1,"/>
 <result pre="States Background: Color vision abnormalities are common among patients with" exact="multiple sclerosis." post="This has been established using several screening tests including"/>
 <result pre="relationship between the FM-100 and other visual outcome measures in" exact="multiple sclerosis" post="(MS) patients who had previously suffered optic neuritis (ON)."/>
 <result pre="measures in multiple sclerosis (MS) patients who had previously suffered" exact="optic neuritis" post="(ON). Methods: Forty six MS patients with stable ON"/>
 <result pre="P663 Retinal ganglion cell layer thinning and vision outcome in" exact="optic neuritis" post="over six months MJ Kupersmith 1, J-K Wang 2,"/>
 <result pre="at presentation and thinning occurs within one month of acute" exact="optic neuritis" post="(ON), long before retinal nerve fiber layer (RNFL) thinning"/>
 <result pre="months were moderately correlated (r=0.48, p =0.02). Conclusions: For acute" exact="optic neuritis," post="the largest proportion of GCL loss has already occurred"/>
 <result pre="to demonstrate early loss; and as an outcome measure of" exact="optic neuritis," post="it shows residual injury better than the RNFL or"/>
 <result pre="motility: a potential method of quantifying progressive cerebral dysfunction in" exact="multiple sclerosis" post="and clinically isolated syndrome M Clough 1, L Mitchell"/>
 <result pre="and SD-OCT between RRMS and PPMS patients with and without" exact="optic neuritis" post="AM Flowers 1, MK Adam 2, RC Sergott 2,3"/>
 <result pre="Ophthalmology and Neurology, Philadelphia, PA, United States Background: Relapsing remitting" exact="multiple sclerosis" post="(RRMS) and primary progressive multiple sclerosis (PPMS) are characterized"/>
 <result pre="States Background: Relapsing remitting multiple sclerosis (RRMS) and primary progressive" exact="multiple sclerosis" post="(PPMS) are characterized by distinct clinical presentations, genetic profiles,"/>
 <result pre="neuroimaging findings. RRMS patients frequently experience visual loss caused by" exact="optic neuritis" post="(ON). In contrast, PPMS patients develop ON much less"/>
 <result pre="5Hospital Clínic de Barcelona, Barcelona, Spain Background: Chronic relapsing inflammatory" exact="optic neuropathy" post="(CRION), recently described, is characterized by subacute inflammatory optic"/>
 <result pre="Clínic de Barcelona, Barcelona, Spain Background: Chronic relapsing inflammatory optic" exact="neuropathy" post="(CRION), recently described, is characterized by subacute inflammatory optic"/>
 <result pre="optic neuropathy (CRION), recently described, is characterized by subacute inflammatory" exact="optic neuropathy," post="bilateral often with prominent pain, and a clinical course"/>
 <result pre="that there not be a evidence of additional neurological deficit," exact="sarcoidosis" post="or systemic autoimmune disease. Objectives: To perform a clinical"/>
 <result pre="be a evidence of additional neurological deficit, sarcoidosis or systemic" exact="autoimmune disease." post="Objectives: To perform a clinical description of CRION by"/>
 <result pre="of CRION by analyzing a serie of patients with recurrent" exact="optic neuritis" post="(ON). Methods: A transversal study was carried out on"/>
 <result pre="62.5%, MRI that were not normal not meet criteria for" exact="multiple sclerosis." post="ANA positivity was found only in one patient, ACE"/>
 <result pre="is to assess the neuroprotective efficacy of amiloride in acute" exact="optic neuritis." post="Objectives: To evaluate structural and electrophysiological correlates of the"/>
 <result pre="system with clinical visual outcomes in the setting of acute" exact="optic neuritis," post="within a phase II neuroprotection trial. Methods: Patients were"/>
 <result pre="trial. Methods: Patients were recruited with a first episode of" exact="optic neuritis," post="and baseline assessments of vision, retinal nerve fibre layer"/>
 <result pre="PERG is more consistently recorded than the PVEP in acute" exact="optic neuritis." post="Inclusion of PERG increases electrophysiological data capture at baseline"/>
 <result pre="electrophysiological data capture at baseline assessment in clinical trials of" exact="optic neuritis," post="and may provide useful structure-function information. SLP derived RNFL"/>
 <result pre="confounded by swelling than OCT in the acute phase of" exact="optic neuritis," post="appears to have a significant correlation with vision in"/>
 <result pre="data. P670 Sector-specific macular volume compromise in relapsing &amp;amp; remitting" exact="multiple sclerosis" post="as measured by optical coherence tomography AS Fjeldstad 1,"/>
 <result pre="volume in Relapsing-Remitting MS (RR-MS) patients with or without prior" exact="optic neuritis" post="(ON), and compare the results to healthy controls. Methods:"/>
 <result pre="ON. In addition, ON findings are consistent with a uniform" exact="neurodegeneration" post="in the perimacular retina. Future OCT studies may focus"/>
 <result pre="well as the individual sector volumes as sensitive measures of" exact="neurodegeneration" post="in MS and ON. P671 The utility of optical"/>
 <result pre="United States Background: Acute monocular visual loss is common in" exact="multiple sclerosis" post="(MS). Differential diagnoses include optic neuritis (ON), arteritic or"/>
 <result pre="loss is common in multiple sclerosis (MS). Differential diagnoses include" exact="optic neuritis" post="(ON), arteritic or non-arteritic ischemic optic neuropathy (AION/NAION), and"/>
 <result pre="Differential diagnoses include optic neuritis (ON), arteritic or non-arteritic ischemic" exact="optic neuropathy" post="(AION/NAION), and central or branch retinal artery occlusion (CRAO/BRAO)."/>
 <result pre="diagnoses include optic neuritis (ON), arteritic or non-arteritic ischemic optic" exact="neuropathy" post="(AION/NAION), and central or branch retinal artery occlusion (CRAO/BRAO)."/>
 <result pre="arteritic or non-arteritic ischemic optic neuropathy (AION/NAION), and central or" exact="branch retinal artery occlusion" post="(CRAO/BRAO). Distinguishing ON from BRAO may be challenging because"/>
 <result pre="because acute retinal whitening can be subtle and transient and" exact="optic atrophy" post="may develop chronically from retrograde axonal degeneration. Objectives: We"/>
 <result pre="Objectives: We present two patients referred to our center for" exact="optic neuropathy" post="where spectral-domain optical coherence tomography (SD-OCT) provided vital clues"/>
 <result pre="We present two patients referred to our center for optic" exact="neuropathy" post="where spectral-domain optical coherence tomography (SD-OCT) provided vital clues"/>
 <result pre="in his left eye was referred with a diagnosis of" exact="optic neuritis." post="Examination revealed reduced visual acuity, color impairment, a paracentral"/>
 <result pre="a diagnosis of NAION and history of a thoracic dissecting" exact="aortic aneurysm" post="2 years prior was referred for evaluation of optic"/>
 <result pre="NAION. Conclusions: OCT imaging of macular layers can help distinguish" exact="optic neuropathy," post="a common finding in MS, from a primary retinal"/>
 <result pre="nervous system (CNS). The clinical presentation is characterized by uveitis," exact="aseptic meningitis," post="hearing loss and sometimes vitiligo and poliosis. It has"/>
 <result pre="is characterized by uveitis, aseptic meningitis, hearing loss and sometimes" exact="vitiligo" post="and poliosis. It has no specific markers and white"/>
 <result pre="early diagnosis of VKHD is underlined by the fact that" exact="uveitis" post="can exert a catastrophic effect on the visual function,"/>
 <result pre="affect the visual pathway and the central nervous system like" exact="multiple sclerosis" post="(MS) or Cogan disease should be ruled out. In"/>
 <result pre="Cogan disease should be ruled out. In any patient with" exact="aseptic meningitis," post="white matter lesions and hearing loss or vertigo, VKHD"/>
 <result pre="two and three way receiver operating characterization (ROC) analyses for" exact="optic neuritis" post="transfer function characterization SH Choudhury 1, B Goodyear 1,"/>
 <result pre="Background: Optic neuritis (ON) represents a single-lesion model to explore" exact="multiple sclerosis" post="(MS). Functional magnetic resonance imaging transfer function (fMRI-TF) measures"/>
 <result pre="can track ON recovery. P674 25-hydroxyvitamin D levels in acute" exact="optic neuritis." post="Relation to paraclinical findings, demographic characteristics and risk of"/>
 <result pre="Denmark Background: The importance of vitamin D in development of" exact="multiple sclerosis" post="(MS) is becoming increasingly accepted. Optic neuritis is a"/>
 <result pre="D (25HVITD) levels in patients in the acute phase of" exact="optic neuritis" post="(ON) with comparisons to a general MS population and"/>
 <result pre="nerve head volume as a marker for neuronal damage after" exact="optic neuritis" post="in multiple sclerosis and neuromyelitis optica HG Zimmermann 1,"/>
 <result pre="as a marker for neuronal damage after optic neuritis in" exact="multiple sclerosis" post="and neuromyelitis optica HG Zimmermann 1, EM Kadas 1,"/>
 <result pre="for neuronal damage after optic neuritis in multiple sclerosis and" exact="neuromyelitis optica" post="HG Zimmermann 1, EM Kadas 1, F Pache 1,"/>
 <result pre="Multiple Sclerosis Research Center, Berlin, Germany Background: Optic neuritis in" exact="multiple sclerosis" post="(MS) and neuromyelitis optica (NMO) leads to thinning of"/>
 <result pre="Berlin, Germany Background: Optic neuritis in multiple sclerosis (MS) and" exact="neuromyelitis optica" post="(NMO) leads to thinning of the retinal nerve fiber"/>
 <result pre="compare ONH volume and RNFL thickness as markers for optic" exact="neurodegeneration" post="in eyes with a history of optic neuritis in"/>
 <result pre="markers for optic neurodegeneration in eyes with a history of" exact="optic neuritis" post="in NMO and relapsing-remitting MS (RRMS). Methods: Seventy-one patients"/>
 <result pre="relapsing-remitting MS (RRMS). Methods: Seventy-one patients with a history of" exact="optic neuritis" post="(49 RRMS and 22 NMO) and 39 healthy controls"/>
 <result pre="was significantly reduced in patients’ eyes with a history of" exact="optic neuritis" post="in comparison to patients’ eyes without in MS (B=0.295,"/>
 <result pre="evoked potentials (VEPs) in assessing visual involvement in patients with" exact="multiple sclerosis" post="(MS). Methods: Cross-sectional study of 121 consecutive subjects with"/>
 <result pre="MS. Of 242 eyes, 166 had no previous history of" exact="optic neuritis" post="(ON), 22 had a single recent ON episode (&amp;lt;"/>
 <result pre="a higher sensitivity of VEPs in the subacute phases of" exact="optic neuritis" post="and in asymptomatic eyes. This discrepancy fades off after"/>
 <result pre="verified through longitudinal studies. P677 Optical coherence tomography after first" exact="optic neuritis" post="for the differentiation between neuromyelitis optica and multiple sclerosis"/>
 <result pre="coherence tomography after first optic neuritis for the differentiation between" exact="neuromyelitis optica" post="and multiple sclerosis NH Kim 1, YJ Shin 2,"/>
 <result pre="first optic neuritis for the differentiation between neuromyelitis optica and" exact="multiple sclerosis" post="NH Kim 1, YJ Shin 2, KS Jeong 3,"/>
 <result pre="(OCT) has been suggested to be useful in discrimination between" exact="neuromyelitis optica" post="(NMO) and multiple sclerosis (MS). However, multiple episodes of"/>
 <result pre="to be useful in discrimination between neuromyelitis optica (NMO) and" exact="multiple sclerosis" post="(MS). However, multiple episodes of optic neuritis (ON) result"/>
 <result pre="optica (NMO) and multiple sclerosis (MS). However, multiple episodes of" exact="optic neuritis" post="(ON) result in cumulative severe reduction of RNFLT, making"/>
 <result pre="enrolled a total of 96 eyes from 48 patients with" exact="multiple sclerosis" post="(48 IFNβ-1b-treated and 48 untreated eyes) and 24 eyes"/>
 <result pre="balance of TNF signalling in cortical grey matter in progressive" exact="multiple sclerosis" post="R Magliozzi 1,2, P Durrenberger 3, O Howell 4,"/>
 <result pre="(GM) pathology is the best correlate of clinical progression in" exact="multiple sclerosis" post="(MS). Recent studies of cortical pathology in secondary progressive"/>
 <result pre="Astrocytes upregulate interleukin-17 receptor expression in white matter lesions in" exact="multiple sclerosis" post="J Raffel 1, R Nicholas 1, F Roncaroli 1,"/>
 <result pre="attracted attention for its putative role in disease pathogenesis in" exact="multiple sclerosis" post="(MS). In humans, post-mortem tissue studies in MS have"/>
 <result pre="and transporter transcripts in normal appearing grey matter of chronic" exact="multiple sclerosis" post="patients R Klaver 1, P Nijland 2, GJ Schenk"/>
 <result pre="Although grey matter (GM) pathology correlates with the progression of" exact="multiple sclerosis" post="(MS), the question remains how does GM pathology arise?"/>
 <result pre="the data on protein level. P684 Podoplanin is expressed in" exact="multiple sclerosis" post="meninges and perivascular infiltrates and regulates T-cell proliferation and"/>
 <result pre="lymphatic system and in the biology of immune cells. In" exact="multiple sclerosis" post="(MS), formation of ectopic meningeal lymphoid follicles is associated"/>
 <result pre="formation of ectopic meningeal lymphoid follicles is associated with accelerated" exact="neurodegeneration" post="and disability progression. Recent work in EAE mice suggests"/>
 <result pre="findings suggest a critical but unknown role for PDPN in" exact="multiple sclerosis." post="Objectives: To characterize expression of PDPN and its ligands"/>
 <result pre="patients. P685 Epigenetic changes control memory function following demyelination in" exact="multiple sclerosis" post="A Chomyk 1, S Deckhard 1, RJ Fox 2,"/>
 <result pre="brains were donated for research purposes (two patients affected by" exact="multiple sclerosis" post="and one by anti-NMDA-r encephalitis): two were sectioned using"/>
 <result pre="changes observed in disease. P688 S100B levels are increased in" exact="multiple sclerosis" post="and modulates demyelination, glial reactivity and inflammation A Barateiro"/>
 <result pre="identified in cerebrospinal fluid (CSF) and post-mortem brain tissue of" exact="multiple sclerosis" post="(MS) patients and correlated with glia reactivity upon demyelination."/>
 <result pre="of retroviral sequences in brain tissue from patients with progressive" exact="multiple sclerosis" post="JD Kriesel 1, PJ Bhetariya 1, BK Chan 1,2,"/>
 <result pre="of total RNA extracted from 12 primary progressive MS, 2" exact="neuromyelitis optica," post="and 14 normal control frozen brain specimens was performed"/>
 <result pre="Differential oxidative stress and cytokine profile between progressive and relapsing-remitting" exact="multiple sclerosis" post="patients AP Kallaur 1, SR Oliveira 2, LJV Schiavão"/>
 <result pre="Although inflammation is the driving force for brain injury in" exact="multiple sclerosis" post="(MS), studies suggest that oxidative stress may also modulate"/>
 <result pre="disease. P691 Neuropathological study of glucose and monocarboxylate transporters in" exact="multiple sclerosis" post="K Masaki 1, SO Suzuki 2, M Watanabe 1,"/>
 <result pre="loss of astrocytic and oligodendrocytic Cxs in active lesions of" exact="multiple sclerosis" post="(MS), neuromyelitis optica (NMO) and Baló’s disease (BD), suggesting"/>
 <result pre="and oligodendrocytic Cxs in active lesions of multiple sclerosis (MS)," exact="neuromyelitis optica" post="(NMO) and Baló’s disease (BD), suggesting early disruption of"/>
 <result pre="Marburg’s type and 20 with other neurological diseases. Results: In" exact="myasthenia gravis" post="case, GLUT1 and MCT1 were abundantly expressed in the"/>
 <result pre="Is inflammation atherogenic in neurological diseases? A case-control study with" exact="migraine" post="and multiple sclerosis patients V González Quintanilla 1, M"/>
 <result pre="atherogenic in neurological diseases? A case-control study with migraine and" exact="multiple sclerosis" post="patients V González Quintanilla 1, M Toriello 1, S"/>
 <result pre="Objectives: To determine the endothelial damage in patients suffering from" exact="multiple sclerosis" post="(MS) and migraine measuring the carotid intima-media thickness (IMT)"/>
 <result pre="endothelial damage in patients suffering from multiple sclerosis (MS) and" exact="migraine" post="measuring the carotid intima-media thickness (IMT) and the endothelial-dependant"/>
 <result pre="and the endothelial-dependant flow-mediated vasodilation (EDV), as subclinical biomarkers of" exact="atherosclerosis" post="and predictors of cardiovascular events. Methods: Subjects were recruited"/>
 <result pre="for MS diagnosis, and ICH-2004 and 2006 criteria for chronic" exact="migraine" post="(CM). A control group were also recruited. Ultrasonografic images"/>
 <result pre="and Pearson regression test. Results: We recruited 22 controls, 59" exact="migraine" post="patients (25 CM), 33 MS patients. IMT was thicker"/>
 <result pre="and FISS PI11/1232 grants. P693 CHI3L1 and SPP1 distribution in" exact="multiple sclerosis" post="lesions I Ahmad 1, S Wergeland 1, L Bø"/>
 <result pre="a secreted glycoprotein that is up-regulated in inflammatory conditions, including" exact="multiple sclerosis" post="(MS). The function of CHI3L1 expression has not been"/>
 <result pre="a similar cellular distribution. P694 Endothelial function in patients with" exact="multiple sclerosis" post="NN Spirina 1, NN Spirin 1, AN Boyko 2,"/>
 <result pre="Federation Background: One of the first theories of pathogenesis of" exact="multiple sclerosis" post="(MS) was a vascular theory. A key step in"/>
 <result pre="(DMT) of MS, a comparative analysis of endothelial function in" exact="multiple sclerosis" post="patients and healthy volunteers. Methods: 33 patients (20 female,"/>
 <result pre="therapeutic interventions in MS. Neurophysiology P695 Visual evoked potentials in" exact="neuromyelitis optica" post="and its spectrum disorders P Albrecht 1, M Ringelstein"/>
 <result pre="Germany Background: Optic neuritis (ON) is a key feature of" exact="neuromyelitis optica" post="(NMO) and its spectrum disorders (NMOSD). It is responsible"/>
 <result pre="the function of the visual pathway. After ON in classical" exact="multiple sclerosis" post="(MS) VEPs typically show prolonged P100 latencies and often"/>
 <result pre="Melsbroek, Melsbroek, Belgium Background: Cognitive impairment affects half of the" exact="multiple sclerosis" post="(MS) population, is difficult to detect and requires extensive"/>
 <result pre="Visual and auditory evoked potentials as related to fatigue in" exact="multiple sclerosis" post="A Pokryszko-Dragan 1, M Bilinska 1, E Gruszka 1,"/>
 <result pre="of Wroclaw, Wroclaw, Poland Background: The origin of fatigue in" exact="multiple sclerosis" post="remains unclear. Disturbed neural conduction within the brain due"/>
 <result pre="evaluate visual and brainstem auditory evoked potentials (VEP, BAEP) in" exact="multiple sclerosis" post="(MS) patients with regards to fatigue and disease-related variables."/>
 <result pre="Modulation of action tremor by repetitive transcranial magnetic stimulation in" exact="multiple sclerosis" post="patients M Gangitano 1, P Ragonese 1, J Battaglini"/>
 <result pre="P699 Heart rate variability analysis in recently diagnosed patients with" exact="multiple sclerosis" post="D Ozbek 1, A Cincin 2, P Kahraman Koytak"/>
 <result pre="score: a promising tool for evaluation of brainstem involvement in" exact="multiple sclerosis" post="I Adamec 1, T Gabelic 1, M Krbot Skoric"/>
 <result pre="involvement. Objectives: Concerning the great importance of brainstem involvement in" exact="multiple sclerosis" post="(MS), the aim of this study was to explore"/>
 <result pre="Toplice, Croatia Background: Signs of autonomic nervous system involvement in" exact="multiple sclerosis" post="(MS) occur in 50-86% of cases. However, frequency of"/>
 <result pre="biomarker used to track visual system function in MS and" exact="optic neuritis" post="patients. Understanding how VEP measures relate to underlying pathology"/>
 <result pre="optic coherence tomography in monitoring involvement of visual pathways in" exact="multiple sclerosis" post="L Leocani 1, S Guerrieri 1, G Di Maggio"/>
 <result pre="in subsequent recording sessions. To apply the procedure to relapsing" exact="multiple sclerosis" post="(MS) patients to measure acute changes of CMCF to"/>
 <result pre="duration and different QRS axis were found in relapsing remitting" exact="multiple sclerosis" post="patients during remission D Obradovic 1, D Spreng 1,"/>
 <result pre="Belgrade, Serbia Background: Autonomic nervous system dysfunction is present in" exact="multiple sclerosis" post="(MS) patients, which may influence the electrocardiography (ECG) pattern."/>
 <result pre="QT interval, QTc interval, QRS axis and the frequency of" exact="right bundle branch block" post="(RBBB) was compared between 101 patients with relapsing-remitting MS"/>
 <result pre="MS. P709 NMDA receptor blockade is neuroprotective in experimental autoimmune" exact="optic neuritis" post="K-W Sühs 1, R Fairless 2, SK Williams 2,"/>
 <result pre="receptor blockers memantine and MK-801, in a rat model of" exact="optic neuritis," post="inducing Experimental autoimmune encephalomyelitis (EAE) by myelin oligodendrocyte glycoprotein"/>
 <result pre="in a rat model of optic neuritis, inducing Experimental autoimmune" exact="encephalomyelitis" post="(EAE) by myelin oligodendrocyte glycoprotein immunization. Methods: Female BN"/>
 <result pre="a gain of function estradiol analog for inducing remyelination in" exact="multiple sclerosis" post="patients SH Nye 1, S Medicetty 2, BD Trapp"/>
 <result pre="clinical trials, yet they impact only the neuroprotective aspects of" exact="multiple sclerosis" post="(MS), rather than the elusive remyelination activity needed to"/>
 <result pre="partly independent of its effect on focal damage in relapsing-remitting" exact="multiple sclerosis" post="patients N De Stefano 1, L Kappos 2, EW"/>
 <result pre="tissue damage coexist in the brain of patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS) and may occur independently. Diffuse damage underlies complex"/>
 <result pre="MS. P712 Anti- SEMA4D antibody ameliorates pathogenic processes related to" exact="multiple sclerosis" post="AS Jonason 1, E Klimatcheva 1, T Fisher 1,"/>
 <result pre="and neuronal degeneration. Antibody neutralization of SEMA4D could, therefore, ameliorate" exact="multiple sclerosis" post="through multiple mechanisms. Objectives: Blocking SEMA4D could promote differentiation"/>
 <result pre="survival and differentiation. In vivo, anti-SEMA4D significantly attenuates experimental autoimmune" exact="encephalomyelitis" post="in multiple rodent models by preserving BBB integrity and"/>
 <result pre="antibody-mediated neutralization of SEMA4D represents a viable therapeutic strategy for" exact="multiple sclerosis." post="To this end, a randomized, placebo-controlled, double blind, single"/>
 <result pre="Neurology, Detroit, MI, United States Background: Patients with relapsing remitting" exact="multiple sclerosis" post="(RRMS) are commonly treated with high doses of intravenous"/>
 <result pre="agonist, in preclinical development for neuroprotective and regenerative therapy of" exact="multiple sclerosis" post="P Fagergren 1, S Tiwari-Woodruff 2, M Osterlund 1"/>
 <result pre="(ER) beta agonists, avoiding the ERalfa mediated increased risk of" exact="cancer" post="and thrombosis, represent a novel neuroregenerative therapy of Multiple"/>
 <result pre="disease symptoms in a rat model of relapsing-remitting experimental autoimmune" exact="encephalomyelitis" post="(RR-EAE), and an in vitro neuroprotection assay. Methods: RR-EAE"/>
 <result pre="MS. P716 The role of vitamin D and gender in" exact="optic neuritis" post="recovery J Burton 1, J Trufyn 2, C Tung"/>
 <result pre="pathway markers. Vitamin D insufficiency is a risk factor for" exact="multiple sclerosis" post="while vitamin D ameliorates inflammation. Assessment of vitamin D"/>
 <result pre="vitamin D ameliorates inflammation. Assessment of vitamin D status in" exact="optic neuritis" post="may support a neuroprotective role as well. Objectives: We"/>
 <result pre="is associated with better OCT outcomes and axonal preservation/recovery after" exact="optic neuritis." post="Outcomes include RNFL thickness, ganglion cell layer (GCL) thickness"/>
 <result pre="cohort study, a total target of 50 patients with acute" exact="optic neuritis" post="undergo OCT to assess RNFL GCL, macular volume (MV)"/>
 <result pre="respectively) versus women. Conclusions: Not surprisingly, vitamin D insufficiency at" exact="optic neuritis" post="onset is associated with greater baseline edema. At 6"/>
 <result pre="confer neuroprotection and/or improved recovery of the optic nerve after" exact="optic neuritis." post="P717 Tissue plasminogen activator (tPA) influences recovery after white"/>
 <result pre="First, we have shown that the outcome of experimental autoimmune" exact="encephalomyelitis" post="(a classical model of MS) is worse in tPA"/>
 <result pre="progression, brain atrophy and relapse rate in patients with relapsing-remitting" exact="multiple sclerosis" post="(MS). LAQ reduces demyelination and axonal damage in mice"/>
 <result pre="aimed at (i) analysing GPR17 expression in the experimental autoimmune" exact="encephalomyelitis" post="(EAE) MS rodent model, and (ii) assessing the functional"/>
 <result pre="is the natural repair mechanism of CNS demyelinated lesions in" exact="multiple sclerosis" post="(MS), but it is often incomplete or even fails."/>
 <result pre="Cleveland, OH, United States Background: A primary pathological feature of" exact="multiple sclerosis" post="is the loss of myelin-producing oligodendrocytes (OL) and myelin"/>
 <result pre="for successful remyelination and repair in demyelinating diseases such as" exact="multiple sclerosis" post="(MS). Understanding the time course of the oligodendrocyte progenitor"/>
 <result pre="degeneration are considered the major cause of neurological disability in" exact="multiple sclerosis" post="(MS). Vitamin D has been shown to modulate relapse"/>
 <result pre="Medical Center Mainz, Neurology, Mainz, Germany Background: Chronic disability in" exact="multiple sclerosis" post="(MS) is due to neuronal degeneration, which is not"/>
 <result pre="specialised cells in the brain responsible for myelinating neurons. In" exact="multiple sclerosis" post="(MS), myelin becomes damaged, and over time, repair of"/>
 <result pre="Neuroprotective effects of hesperidin in a C57BL/6 mouse model of" exact="multiple sclerosis" post="O Ciftci 1, C Ozcan 2, O Kamisli 2,"/>
 <result pre="Health, Directorate of Health Services, Ankara, Turkey Background: Experimental allergic" exact="encephalomyelitis" post="(EAE) is a T cell-mediated inflammatory demyelinating autoimmune disease"/>
 <result pre="Experimental allergic encephalomyelitis (EAE) is a T cell-mediated inflammatory demyelinating" exact="autoimmune disease" post="that serves as an animal model for multiple sclerosis"/>
 <result pre="demyelinating autoimmune disease that serves as an animal model for" exact="multiple sclerosis" post="(MS). Destruction of myelin sheaths and oligodendrocytes as well"/>
 <result pre="(MS). Destruction of myelin sheaths and oligodendrocytes as well as" exact="neurodegeneration" post="in MS are associated with massive oxidative stress and"/>
 <result pre="anti-inflammatory compounds such as flavonoids may protects nervous system against" exact="autoimmune disease" post="such as MS. Hesperidin (HP) is a bioflavonoid found"/>
 <result pre="and HP+EAE. After induction of EAE with (MOG 35-55) and" exact="pertussis" post="toxin, the mice treated with HP at the doses"/>
 <result pre="Zentrum, Klinik und Poliklinik fur Neurologie, Dresden, Germany Background: Acute" exact="optic neuritis" post="(AON) is characterized by inflammatory demyelinating and axonal injury"/>
 <result pre="of AON. P732 Production of differential screening-selected gene aberrative in" exact="neuroblastoma" post="(DAN) in the CNS may support neurogenesis/ oligodendrogenesis in"/>
 <result pre="School, Tel Aviv, Israel Background: The inadequate tissue repair of" exact="multiple sclerosis" post="(MS) lesions is assumed to be, in part, due"/>
 <result pre="oligodendrogenesis and neurogenesis. BMP-2,4,5 are upregulated in immune cells of" exact="multiple sclerosis" post="patients, while their antagonists, noggin and follistatin, are down"/>
 <result pre="down regulated in these cells. Differential screening-selected gene aberrative in" exact="neuroblastoma" post="(DAN) is a member of the DAN family of"/>
 <result pre="secreted glycoproteins that are putative BMP antagonists. Its role in" exact="multiple sclerosis" post="has not yet been studied. Objectives: To study the"/>
 <result pre="P733 Predictors of fear of sexual rejection in individuals with" exact="multiple sclerosis" post="S Flood 1, H Quinn 1, E Mendelowitz 1,"/>
 <result pre="Sciences, Winnipeg, MB, Canada Background: Multiple Sclerosis (MS) is an" exact="autoimmune disease" post="of the central nervous system that is often associated"/>
 <result pre="sexual rejection. P734 Development of the neurological coping index for" exact="multiple sclerosis" post="(NCI-MS) CA Young 1,2, A Tennant 3, Trajectories of"/>
 <result pre="P735 Psychiatric diagnoses, medication and risk for disability pension in" exact="multiple sclerosis" post="patients; a population-based register study P Brenner 1, J"/>
 <result pre="Clinical Neuroscience, Stockholm, Sweden Background: Psychiatric comorbidity is common among" exact="multiple sclerosis" post="(MS) patients. The majority of MS patients of working"/>
 <result pre="as well as in a societal perspective. P736 Depression and" exact="multiple sclerosis" post="in the CombiRx study L Stone 1, SS Cofield"/>
 <result pre="TX, United States Background: Depression is common in persons with" exact="multiple sclerosis" post="(MS). Severity can change overtime and be related to"/>
 <result pre="traits are associated with the quality of patient-provider relationships in" exact="multiple sclerosis" post="C Ray 1, S O’Bryan 1, C Mavis 1,"/>
 <result pre="use as a means of coping. Methods: Seventy-seven individuals with" exact="multiple sclerosis" post="(MS) were administered the NEO Five Factor Inventory, the"/>
 <result pre="interventions. P739 Depression correlate with disability and clinical course in" exact="multiple sclerosis" post="patients: an Italian multicenters study C Solaro 1, Neuropathic"/>
 <result pre="people with MS. P740 Does anxiety moderate the relationship between" exact="bowel dysfunction" post="and illness intrusiveness in multiple sclerosis? AS Castiglione 1,"/>
 <result pre="moderate the relationship between bowel dysfunction and illness intrusiveness in" exact="multiple sclerosis?" post="AS Castiglione 1, ES Gromisch 2, V Zemon 2,"/>
 <result pre="York, NY, United States Background: Patients with MS often experience" exact="bowel dysfunction," post="with fecal incontinence and constipation the two most prevalent"/>
 <result pre="with MS often experience bowel dysfunction, with fecal incontinence and" exact="constipation" post="the two most prevalent symptoms. Patients may experience bowel"/>
 <result pre="by the Beck Depression Inventory-II (BDI-II), moderating the relationship between" exact="bowel dysfunction" post="and illness intrusiveness. Objectives: To examine the relationship between"/>
 <result pre="illness intrusiveness. Objectives: To examine the relationship between anxiety and" exact="bowel dysfunction," post="and how that relationship contributes to perceived illness intrusiveness."/>
 <result pre="the Incapacity Status Scale (ISS). Moderation analyses were run with" exact="bowel dysfunction" post="as the predictor, anxiety as measured by the Hospital"/>
 <result pre="score was 7.93 ± 3.75 (range: 0-20). The interaction between" exact="bowel dysfunction" post="and anxiety was significant, F (3, 204) = 19.34,"/>
 <result pre="intrusiveness individually. Anxiety also acted as a significant moderator between" exact="bowel dysfunction" post="and illness intrusiveness. This finding highlights the need to"/>
 <result pre="measure of worry across a broad range of disability in" exact="multiple sclerosis" post="I Pomeroy 1,2, A Tennant 3, CA Young 1,2,"/>
 <result pre="is a construct that is distinct from a multidimensional generalised" exact="anxiety disorder." post="Although generalised anxiety disorder is known to be common"/>
 <result pre="is distinct from a multidimensional generalised anxiety disorder. Although generalised" exact="anxiety disorder" post="is known to be common in multiple sclerosis (MS),"/>
 <result pre="Although generalised anxiety disorder is known to be common in" exact="multiple sclerosis" post="(MS), chronic worry has not been extensively studied in"/>
 <result pre="burden and satisfaction with treatment in caregivers and patients with" exact="multiple sclerosis." post="MS-feeling study J Meca-Lallana 1, M Mendibe 2 1Hospital"/>
 <result pre="Cruces, Cruces, Spain Background: In chronic illnesses such as relapsing-remitting" exact="multiple sclerosis" post="(RRMS), caregiver burden is associated with the disease control"/>
 <result pre="prospective Study aims to describe outcomes after first episode of" exact="acute disseminated encephalomyelitis" post="(ADEM); transverse myelitis (TM); optic neuritis (ON); other clinically"/>
 <result pre="aims to describe outcomes after first episode of acute disseminated" exact="encephalomyelitis" post="(ADEM); transverse myelitis (TM); optic neuritis (ON); other clinically"/>
 <result pre="outcomes after first episode of acute disseminated encephalomyelitis (ADEM); transverse" exact="myelitis" post="(TM); optic neuritis (ON); other clinically isolated syndrome (CIS);"/>
 <result pre="first episode of acute disseminated encephalomyelitis (ADEM); transverse myelitis (TM);" exact="optic neuritis" post="(ON); other clinically isolated syndrome (CIS); neuromyelitis optica (NMO)."/>
 <result pre="myelitis (TM); optic neuritis (ON); other clinically isolated syndrome (CIS);" exact="neuromyelitis optica" post="(NMO). Objectives: To test the hypothesis that children with"/>
 <result pre="more common among the youngest. P745 Cognitive impairment in pediatric" exact="multiple sclerosis" post="patients is not related to cortical lesions MA Rocca"/>
 <result pre="a relationship between educational attainment and employment in adults with" exact="multiple sclerosis" post="(MS), with the underlying hypothesis that progressive MS pathology"/>
 <result pre="subsequent employment. P747 Vitamin D status as a predictor of" exact="multiple sclerosis" post="outcome in children with acute demyelinating syndromes: a prospective"/>
 <result pre="Background: Vitamin D may be a protective etiologic factor for" exact="multiple sclerosis" post="(MS). Acute demyelinating syndromes (ADS) of the CNS represent"/>
 <result pre="possibly reduce risk of MS. P748 Puberty onset and pediatric" exact="multiple sclerosis" post="course S Lulu 1, J Graves 1, E Waubant"/>
 <result pre="new insights in important factors regulating disease processes. P749 Recurrent" exact="optic neuritis" post="in children L Benson 1, G Heidary 1, J"/>
 <result pre="States, 9Boston Children’s Hospital, Boston, MA, United States Background: Recurrent" exact="optic neuritis" post="(ON) occurs in children without MS or NMO, yet"/>
 <result pre="and treatment of the disease. P750 Behavioral ratings in pediatric" exact="multiple sclerosis" post="(MS) MW Porter 1,2, LE Charvet 1,2, D Serafin"/>
 <result pre="Stony Brook, Stony Brook, NY, United States Background: Acute disseminated" exact="encephalomyelitis" post="(ADEM) is an inflammatory demyelinating disease of the CNS"/>
 <result pre="by EDSS. P752 Assessing long-term functional outcomes in children with" exact="acute disseminated encephalomyelitis" post="CS Beatty 1, AS Drake 1, D Ramasamy 1,"/>
 <result pre="P752 Assessing long-term functional outcomes in children with acute disseminated" exact="encephalomyelitis" post="CS Beatty 1, AS Drake 1, D Ramasamy 1,"/>
 <result pre="warranted. P753 A case-control study for risk factors of pediatric" exact="multiple sclerosis" post="in Iran: highlighting the role of puberty M Fereidan-Esfahani"/>
 <result pre="of Background: Although several studies have assessed risk factors for" exact="multiple sclerosis" post="(MS) in adult, there is a lack of data"/>
 <result pre="of MS in who had the positive medical history of" exact="rubella" post="before puberty (OR= 5.206, 95% CI: 1.540-17.601). Finally, mode"/>
 <result pre="P754 Sex related differences in T2 lesion load in pediatric" exact="multiple sclerosis" post="patients HM Hummel 1, P Huppke 1, T Friede"/>
 <result pre="Statistics, Göttingen, Germany Background: A preponderance of females affected by" exact="multiple sclerosis" post="is well reviewed. Several studies have shown an equal"/>
 <result pre="been performed exploring possible differences in the MRI presentation of" exact="multiple sclerosis" post="in boys and girls. Objectives: To study sex-and age"/>
 <result pre="Objectives: To study sex-and age related differences in pediatric relapsing-remitting" exact="multiple sclerosis" post="before and after puberty. Methods: Single center retrospective study"/>
 <result pre="six month after disease manifestation in 178 children with definite" exact="multiple sclerosis" post="recruited by the Center for Multiple Sclerosis in Childhood"/>
 <result pre="in brain volume in a cohort of pediatric patients with" exact="multiple sclerosis" post="(MS), clinical isolated syndromes (CIS), acute disseminated encephalomyelitis (ADEM),"/>
 <result pre="pediatric patients with multiple sclerosis (MS), clinical isolated syndromes (CIS)," exact="acute disseminated encephalomyelitis" post="(ADEM), and other neurological disorders (OND). Methods: In this"/>
 <result pre="with multiple sclerosis (MS), clinical isolated syndromes (CIS), acute disseminated" exact="encephalomyelitis" post="(ADEM), and other neurological disorders (OND). Methods: In this"/>
 <result pre="OND group included 10 headache, 6 seizure and 3 CNS" exact="vasculitis" post="patients. MRI was performed at baseline, with 2 and"/>
 <result pre="been recently FDA approved for the treatment of adults with" exact="multiple sclerosis" post="(MS). Objectives: To evaluate safety, tolerability and preliminary efficacy"/>
 <result pre="(n=1), GI symptoms (nausea, vomiting, abdominal pain) (n= 7), and" exact="rash" post="(n=2). Three patients discontinued (D/C) the oral DMTs; 1"/>
 <result pre="is one of the most common symptoms in children with" exact="multiple sclerosis" post="(MS) and after acute disseminated encephalomeyelitis (ADEM). In children,"/>
 <result pre="intracranial volume) is linked to level of disability on the" exact="multiple sclerosis" post="functional composite JF Sumowski 1, CS Riley 2, G"/>
 <result pre="Background: Physical disability is prevalent but variable across patients with" exact="multiple sclerosis" post="(MS), even among patients with comparable disease burden. This"/>
 <result pre="Philadelphia, Philadelphia, PA, United States Background: MRI features of pediatric-onset" exact="multiple sclerosis" post="(MS) are well understood, and recent work has focused"/>
 <result pre="less well studied. Early predictors of outcome in children with" exact="multiple sclerosis" post="have implications for clinical care and for identifying eligible"/>
 <result pre="treatment decisions. P762 Possible prognostic factors for visual function after" exact="optic neuritis" post="GH Dale 1, K Bacher Svendsen 1, T Bek"/>
 <result pre="T Petersen 1 1Aarhus University Hospital, Aarhus, Denmark Background: Acute" exact="optic neuritis" post="(ON) may lead to permanent visual impairment, but suitable"/>
 <result pre="prognostic marker for BCVA 6 months after an episode of" exact="optic neuritis." post="Contrast sensitivity and the overall classification of RNFLT, does"/>
 <result pre="Unit, Genoa, Italy Background: Early identification of patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS) who are at risk of disease progression may"/>
 <result pre="Biostatistics Unit, Genoa, Italy Background: Timely identification of patients with" exact="multiple sclerosis" post="(MS) who are at risk of poor outcomes facilitates"/>
 <result pre="resonance imaging (MRI) has improved the diagnosis and monitoring of" exact="multiple sclerosis" post="(MS). Parameters usually studied are weakly correlated with physical"/>
 <result pre="test and 9HPT. P768 A clinical prediction model for definite" exact="multiple sclerosis" post="in patients with clinically isolated syndrome TF Runia 1,"/>
 <result pre="Clinically isolated syndrome (CIS) is often the first manifestation of" exact="multiple sclerosis" post="(MS). However, not all patients with CIS will go"/>
 <result pre="not all patients with CIS will go on to develop" exact="multiple sclerosis" post="(MS). The uncertainty about whether or not a CIS"/>
 <result pre="early start of immunomodulatory treatment. P769 Predicting clinical course in" exact="multiple sclerosis" post="using machine learning T Chitnis 1, Y Zhao 2,"/>
 <result pre="To explore the utility of machine-learning techniques to reliably predict" exact="multiple sclerosis" post="disease progression status at up to five years of"/>
 <result pre="the most relevant surrogate markers for conversion to clinically definite" exact="multiple sclerosis" post="(CDMS) and development of sustained disability progression (SDP). Investigation"/>
 <result pre="also associated with SDP. P771 Predictors of disability accrual in" exact="multiple sclerosis" post="patients on first-line therapy T Spelman 1, V Jokubaitis"/>
 <result pre="principal objective when managing the clinical care of people with" exact="multiple sclerosis" post="(MS) is to prevent the irreversible accumulation of neurological"/>
 <result pre="expanded disability status scale (EDSS) change in patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS) treated with any interferon-beta (IFNβ) preparation or glatiramer"/>
 <result pre="and QOL P772 Psychosocial factors affecting quality of life in" exact="multiple sclerosis" post="- a review of the current evidence base CA"/>
 <result pre="predict the perceived health-related quality of life in persons with" exact="multiple sclerosis" post="IR Zarbo 1,2, S Demontis 3, G Carpentras 3,"/>
 <result pre="Canada, 7University of Manitoba, Winnipeg, MB, Canada Background: Persons with" exact="multiple sclerosis" post="(MS) report lower health-related quality of life (HRQoL) than"/>
 <result pre="undergone extensive psychometric testing but their performance in persons with" exact="multiple sclerosis" post="(MS) with a range of cognitive impairment has not"/>
 <result pre="Denmark Background: Ambulatory impairment is common in patients with secondary-progressive" exact="multiple sclerosis" post="(SPMS). In the ASCEND study of patients with SPMS,"/>
 <result pre="6MWT distance. P778 Longitudinal course of depression and fatigue in" exact="multiple sclerosis" post="EE Greeke 1, AS Chua 1, BC Healy 1,"/>
 <result pre="Background: Depression and fatigue are commonly reported in patients with" exact="multiple sclerosis" post="(MS). Although there are numerous studies looking at the"/>
 <result pre="of patient-reported symptoms and impairment in relapsing-remitting and secondary progressive" exact="multiple sclerosis" post="HJ Gross 1, C Watson 2 1Kantar Health, Princeton,"/>
 <result pre="(88.6% vs 69.9%; P=0.001); muscle spasms (74.3% vs 54.1%; P=0.001);" exact="sexual dysfunction" post="(33.3% vs 22.7%; P=0.023); stiffness (56.2% vs 34.9%; P&amp;lt;"/>
 <result pre="(56.2% vs 34.9%; P&amp;lt; 0.001); tremor (25.7% vs 15.3%; P=0.011);" exact="constipation" post="(51.4% vs 28.2%; P&amp;lt; 0.001); and urinary incontinence or"/>
 <result pre="Idec Inc. P780 Cognition and fatigue in patients with relapsing" exact="multiple sclerosis" post="treated by subcutaneous interferon beta-1a: an observational study SKORE"/>
 <result pre="r.o., Prague, Czech Republic Background: Cognitive impairment often occurs in" exact="multiple sclerosis" post="(MS) patients, even in the early stages of the"/>
 <result pre="of Liverpool, Liverpool, United Kingdom Background: 70-80% of patients with" exact="multiple sclerosis" post="(MS) will experience some lower urinary tract symptoms (LUTS)"/>
 <result pre="P784 Psychometric testing of the early mobility impairment questionnaire for" exact="multiple sclerosis" post="T Ziemssen 1, A Mathias 2, C Coon 2,"/>
 <result pre="University, MS, United States Background: Nearly all subjects (93%) with" exact="multiple sclerosis" post="(MS) experience some degree of mobility impairment—over half (58%)"/>
 <result pre="2004;42(9):851-859 P786 Psychometric properties of the French version of the" exact="multiple sclerosis" post="knowledge questionnaire Y Bourhis 1, S Chrétin 1, S"/>
 <result pre="France, 3Hôpital Central, Nancy, France Background: Improving patient information about" exact="multiple sclerosis" post="(MS) requires reliable assessment of patient knowledge. The Multiple"/>
 <result pre="investigated. P787 Rasch analysis of the Leeds Spasticity Scale in" exact="multiple sclerosis" post="RJ Mills 1, K Milinis 2,3, A Tennant 4,"/>
 <result pre="longer form measures. P788 Dalfampridine improves spasticity and fatigue in" exact="multiple sclerosis" post="M-A Guyot 1, C Donzé 1, H Khenioui 1,"/>
 <result pre="Lomme, France Background: Fatigue and spasticity are common symptoms in" exact="multiple sclerosis" post="(MS) with significant impairment of quality of life. Objectives:"/>
 <result pre="P789 Evaluation of the health related quality of life in" exact="neuromyelitis optica" post="spectrum disorder S-Y Huh 1, HJ Kim 2, J"/>
 <result pre="of care provided to patients with chronic disease such as" exact="neuromyelitis optica" post="spectrum disorder (NMOSD). However, there have been limited studies"/>
 <result pre="interim analysis of quality of life in patients with relapsing-remitting" exact="multiple sclerosis" post="treated with delayed-release dimethyl fumarate SP Sarda 6, M"/>
 <result pre="a 24-months, non-interventional study in 1705 patients with relapsing remitting" exact="multiple sclerosis" post="(RRMS). Of 1705 patients, 1214 patients used injectable interferon"/>
 <result pre="been reported, but the prevalence of specific symptoms in relapsing-remitting" exact="multiple sclerosis" post="(RRMS), how they are related to one another, and"/>
 <result pre="and their impact on quality of life in patients with" exact="multiple sclerosis" post="N Oztekin 1, MF Oztekin 2, E Eruyar 1,"/>
 <result pre="acetate (GA) and interferon-beta (IFN-β) are disease-modifying therapies (DMTs) for" exact="multiple sclerosis" post="that are administered through subcutaneous (SC) or intramuscular (IM)"/>
 <result pre="QoL. Methods: It is a longutudinal study among patients with" exact="multiple sclerosis" post="who had been treated with their first DMT for"/>
 <result pre="times a week (p&amp;lt; 0.05). The other side effects were" exact="anemia" post="and leucopenia (60 %), 40% in patients using GA"/>
 <result pre="the FSMC. P796 Development of the neurological hope index for" exact="multiple sclerosis" post="(NHI-MS) CA Young 1,2, A Tennant 3, Trajectories of"/>
 <result pre="of the WHO Disability Assessment Schedule 2.0 for use in" exact="multiple sclerosis" post="CJ Gibbons 1, R Mills 2, A Tennant 3,"/>
 <result pre="study evaluated the suitability of this measure for use in" exact="multiple sclerosis" post="(MS) by applying scale data to the Rasch model,"/>
 <result pre="(AEs) associated with interferon beta treatments (IFN) in patients with" exact="multiple sclerosis" post="(MS) and may have a negative effect on patients’"/>
 <result pre="4University of Manitoba, Winnipeg, MB, Canada Background: Persons living with" exact="multiple sclerosis" post="(MS) frequently experience bladder dysfunction which can vary in"/>
 <result pre="and sexual problems in 2010. P801 New sleep scales for" exact="multiple sclerosis" post="RJ Mills 1, A Tennant 2, CA Young 3,"/>
 <result pre="There is an intimate relationship between fatigue and sleep in" exact="multiple sclerosis" post="(MS). During the construction of the Neurological Fatigue Index"/>
 <result pre="approved in over 30 countries for the treatment of relapsing-remitting" exact="multiple sclerosis" post="(RRMS). In the 2-year phase 3 CARE-MS II study,"/>
 <result pre="relapses and quality of life in patients with relapsing remitting" exact="multiple sclerosis" post="L Grau-Lopez 1, M Tintoré 2, L Ramió-Torrentà 3,"/>
 <result pre="relapses in quality of life of patients with relapsing remitting" exact="multiple sclerosis." post="Methods: Forty-nine MS patients with a relapse included in"/>
 <result pre="2Biogen Idec Inc., Cambridge, MA, United States Background: Patients with" exact="multiple sclerosis" post="(MS) often report diminished health-related quality of life (HRQoL)."/>
 <result pre="the general US population. P806 Italian validation of the 12-item" exact="multiple sclerosis" post="walking scale (MSWS-12) E Trabucco 1, M Cella 1,"/>
 <result pre="been commonly reported in the lower limbs of people with" exact="multiple sclerosis" post="(MS). CMI is typically documented based on performing a"/>
 <result pre="disability status. P808 Corticospinal reserve predicts walking improvement in progressive" exact="multiple sclerosis" post="patients undergoing neurorehabilitation and deep rTMS with H-coil A"/>
 <result pre="Background: Walking impairment affect up to 85% of subjects with" exact="multiple sclerosis" post="- MS - with a major impact on their"/>
 <result pre="P809 Efficacy of mental imagery to improve autobiographical memory in" exact="multiple sclerosis" post="patients: a double approach in neuropsychology and neuroimaging A"/>
 <result pre="We previously showed autobiographical memory (AM) impairment in non-depressed relapsing-remitting" exact="multiple sclerosis" post="(RR-MS) patients, very likely caused by a retrieval-strategy deficit."/>
 <result pre="Republic Background: Gait abnormalities are a common feature of the" exact="multiple sclerosis" post="(MS) patients. Even MS patients with minimal clinical disability"/>
 <result pre="validity of the narrow path walking test for people with" exact="multiple sclerosis" post="U Rosenblum 1,2, I Melzer 2, A Achiron 1,3"/>
 <result pre="scores. P812 Visual delay adaptation to reduce intention tremor in" exact="multiple sclerosis" post="M Heenan 1, R Scheidt 1,2,3, S Beardsley 1,4,5"/>
 <result pre="tremor is a disabling symptom affecting ~15% of those with" exact="multiple sclerosis" post="(MS). Our previous work has shown that tremor may"/>
 <result pre="A novel characterization of gait pattern alterations in individuals with" exact="multiple sclerosis" post="based on quantitative movement analysis M Pau 1, G"/>
 <result pre="P815 Factors affecting physical activity in minimally impaired people with" exact="multiple sclerosis" post="T Kahraman 1, S Savci 1, E Coskuner Poyraz"/>
 <result pre="known benefits of physical activity, evidence shows that people with" exact="multiple sclerosis" post="(pwMS) are relatively inactive. There are several studies about"/>
 <result pre="Sclerosis Center, Sheba Medical Center, Tel-Hashomer, Israel Background: People with" exact="multiple sclerosis" post="(MS) identify mobility limitations as one of the greatest"/>
 <result pre="level of concern. P819 Brain activity during motor imagery in" exact="multiple sclerosis" post="G Brichetto 1, A Tacchino 1, R Teodorescu 2,"/>
 <result pre="Neuropsychological and neurophysiological assessment of a cognitive rehabilitation program for" exact="multiple sclerosis" post="patients M Vazquez-Marrufo 1, A Galvao-Carmona 1, M Borges"/>
 <result pre="Sclerosis Unit, Seville, Spain Background: Cognitive impairment is common in" exact="multiple sclerosis" post="patients. One of the main challenges nowadays is to"/>
 <result pre="of applying a cognitive rehabilitation program to a sample of" exact="multiple sclerosis" post="patients. Methods: Thirty-three subjects were assigned to three groups"/>
 <result pre="of gait during a long distance walk in persons with" exact="multiple sclerosis" post="JM Wagner 1, V Levasseur 2, G Adusumilli 2,"/>
 <result pre="Gonda Brain Research Center, Ramat Gan, Israel Background: Persons with" exact="multiple sclerosis" post="(pwMS) have difficulties walking long distances yet the specific"/>
 <result pre="Kansas City, KS, United States Background: Up to 65% of" exact="multiple sclerosis" post="(MS) patients experience cognitive deficits associated in the disease,"/>
 <result pre="The relationship between core stability and balance in patients with" exact="multiple sclerosis" post="G Yazici 1, A Guclu-Gunduz 1, C Ozkul 1,"/>
 <result pre="United States Background: The chronic, progressive, and variable nature of" exact="multiple sclerosis" post="(MS) underscores the importance of establishing strong relationships between"/>
 <result pre="medicine: enabling evidence-based and individualized treatment decisions for patients with" exact="multiple sclerosis" post="V Viglietta 1, K Raghupathi 1, W Gabel 1,"/>
 <result pre="to a rapid expansion in available treatments for patients with" exact="multiple sclerosis" post="(MS) in recent years. However, benefit-risk profiles are not"/>
 <result pre="treatment decision making will be presented. P826 Do patients with" exact="multiple sclerosis" post="understand quantitative health information? A comparison of patients with"/>
 <result pre="Background: Natalizumab (NAT) is a highly effective therapy in relapsing" exact="multiple sclerosis" post="(MS), yet bears the risk of a progressive multifocal"/>
 <result pre="relapsing multiple sclerosis (MS), yet bears the risk of a" exact="progressive multifocal leukoencephalopathy" post="as a rare but severe side effect. To make"/>
 <result pre="of data from an adult day program for people with" exact="multiple sclerosis" post="D Burke 1, S Minden 1, M Serotkin 2,"/>
 <result pre="adherence and persistence. P829 Aerobic fitness and hippocampal volume in" exact="multiple sclerosis" post="RW Motl 1, B Sutton 1, E Hubbard 1,"/>
 <result pre="States Background: The hippocampus is important for memory functions in" exact="multiple sclerosis" post="(MS). Importantly, there is significant atrophy of this structure"/>
 <result pre="Background: Falls are a significant health concern for individuals with" exact="multiple sclerosis" post="(IwMS) and have been associated with physical injury, fear"/>
 <result pre="among non-ambulatory IwMS. P832 Low-cost portable posturography for patients with" exact="multiple sclerosis" post="using Wii balance board L Prosperini 1, L Stocchi"/>
 <result pre="objective and specific outcome measures for balance of patients with" exact="multiple sclerosis" post="(MS). Despite this, the lack of standardisation, heterogeneity of"/>
 <result pre="of fascial mobilization on dynamic walking parameters in patients with" exact="multiple sclerosis" post="H Keklicek 1, Y Salci 1, A Fil 1,"/>
 <result pre="Vitamin D serum levels and balance are not related in" exact="multiple sclerosis" post="G Coghe 1, M Pau 2, E Cocco 1,"/>
 <result pre="and efficacy of working memory training for individuals with pediatric-onset" exact="multiple sclerosis" post="B Kuni 1, A Sye 2, EA Yeh 2,3,4,"/>
 <result pre="a relationship between cognitive and motor performance in persons with" exact="multiple sclerosis" post="(MS), generally using as experimental setting the dual task"/>
 <result pre="and pregnancy P838 Glatiramer acetate and pregnancy in women with" exact="multiple sclerosis" post="- results from the German multiple sclerosis and pregnancy"/>
 <result pre="in women with multiple sclerosis - results from the German" exact="multiple sclerosis" post="and pregnancy registry S Herbstritt 1,2, M Rockhoff 1,"/>
 <result pre="Pharmacy, Toronto, ON, Canada Background: MS is the most common" exact="autoimmune disease" post="of the central nervous system, which mainly affects young"/>
 <result pre="of glatiramer acetate (GLAT) exposure during pregnancy of patients with" exact="multiple sclerosis" post="(MS). Methods: We compared the outcome of pregnancies of"/>
 <result pre="were born with malformations of non-genetic origin: 2 with an" exact="atrial septal defect," post="1 with dysmelia of tibia and fibula of the"/>
 <result pre="of childbearing age make up a large proportion of the" exact="multiple sclerosis" post="population, it is important to evaluate effects of delayed-release"/>
 <result pre="Clinical studies of delayed-release DMF included 2,665 MS patients, 320" exact="psoriasis" post="patients, 101 rheumatoid arthritis patients, and 338 healthy volunteers;"/>
 <result pre="delayed-release DMF included 2,665 MS patients, 320 psoriasis patients, 101" exact="rheumatoid arthritis" post="patients, and 338 healthy volunteers; subjects were required to"/>
 <result pre="DMF included 2,665 MS patients, 320 psoriasis patients, 101 rheumatoid" exact="arthritis" post="patients, and 338 healthy volunteers; subjects were required to"/>
 <result pre="MA, United States Background: Almost half of women living with" exact="multiple sclerosis" post="(MS) are post-menopausal. While puberty and pregnancy represent key"/>
 <result pre="to explore a potential role for HRT. P841 Risk of" exact="neuromyelitis optica" post="spectrum disorder relapse associated with pregnancy on Japanese patients"/>
 <result pre="describing the influence of pregnancy on the clinical course of" exact="neuromyelitis optica" post="spectrum disorder (NMOSD). Previously reports reviewed the annualized relapse"/>
 <result pre="Alemtuzumab, approved in over 30 countries for treatment of relapsing-remitting" exact="multiple sclerosis" post="(RRMS), showed superior efficacy over subcutaneous interferon beta-1a (SC"/>
 <result pre="and disease activity after exposure to natalizumab in patients with" exact="multiple sclerosis" post="E Portaccio 1, B Hakiki 1, L Pastò 1,"/>
 <result pre="and disease activity after in utero exposure to natalizuamb in" exact="multiple sclerosis" post="(MS) patients. Objectives: To assess the impact of natalizumab"/>
 <result pre="during and after pregnancy are ongoing. P844 Pregnancy issues in" exact="multiple sclerosis" post="patients: preliminary results from a multicenter retrospective cohort study"/>
 <result pre="and to higher rates of elective abortion rather than to" exact="infertility" post="issues. P845 Sex life of women with multiple sclerosis:"/>
 <result pre="tremor, muscle weakness, sensorial disorders, depression, cognitive problems, bladder and" exact="bowel dysfunction" post="and sexual dysfunction are commonly seen in multiple sclerosis"/>
 <result pre="sensorial disorders, depression, cognitive problems, bladder and bowel dysfunction and" exact="sexual dysfunction" post="are commonly seen in multiple sclerosis (MS) and these"/>
 <result pre="and bowel dysfunction and sexual dysfunction are commonly seen in" exact="multiple sclerosis" post="(MS) and these conditions significantly affect the quality of"/>
 <result pre="Background: Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting" exact="multiple sclerosis" post="(MS). Evidence from animal studies suggests a potential risk"/>
 <result pre="pregnancies in the post-marketing setting. P847 Exclusive breastfeeding and postpartum" exact="multiple sclerosis" post="relapses K Hellwig 1, M Rockhoff 1, S Herbstritt"/>
 <result pre="Department Kaiser Permanente, Pasadena, CA, United States Background: Women with" exact="multiple sclerosis" post="(MS) experience an elevated relapse risk after birth. The"/>
 <result pre="postpartum relapses. P848 Ovarian reserve and sex hormone levels in" exact="multiple sclerosis" post="patients M Sepulveda 1, E Hernández 1, M Hervàs"/>
 <result pre="causes associated with impairment of the fertility in women with" exact="multiple sclerosis" post="(MS). However, the ovarian reserve, a measure of the"/>
 <result pre="with gonadotoxic treatments and/or had a history of any known" exact="endocrine disease" post="or infertility (e.g., polycystic ovary syndrome). MS patients were"/>
 <result pre="and/or had a history of any known endocrine disease or" exact="infertility" post="(e.g., polycystic ovary syndrome). MS patients were free from"/>
 <result pre="the prime of their sexual lives. Objectives: In everyday practice" exact="sexual dysfunction" post="is underestimated because clinicians mostly concentrate on the classical"/>
 <result pre="We included in our study 97 patients with relapse remitting" exact="multiple sclerosis" post="from our MS register, 22 men and 75 women"/>
 <result pre="men and 75 women with established diagnosis of relapse remitting" exact="multiple sclerosis" post="according to McDonald criteria. Patients completed the questionnaires (Sexual"/>
 <result pre="without aid, self sufficient patients) we found positive correlation between" exact="sexual dysfunction" post="and depression showing that even in such patients quality"/>
 <result pre="order to improve their quality of life. P850 Prevalence of" exact="sexual dysfunction" post="in multiple sclerosis RAP da Silva 1, LP Stievano"/>
 <result pre="their quality of life. P850 Prevalence of sexual dysfunction in" exact="multiple sclerosis" post="RAP da Silva 1, LP Stievano 1, GS do"/>
 <result pre="social, family and emotional relationships. It was observed that the" exact="sexual dysfunction" post="(SD) affects 82 to 91% of men and 59"/>
 <result pre="life interfere with sexual health of these patients. Objectives: Assess" exact="sexual dysfunction" post="by The Multiple Sclerosis Intimicy and Sexuality Questionnaire-19 (MSISQ-19),"/>
 <result pre="group and 134 patients with MS. Results: The incidence of" exact="sexual dysfunction" post="in our study was 72% in women and 54%"/>
 <result pre="be used as a tool for assessing the impact of" exact="sexual dysfunction" post="in patients with MS.Most research suggests that MS has"/>
 <result pre="important to consider, however, that despite the high prevalence of" exact="sexual dysfunction" post="in MS, we should not neglect other conditions that"/>
 <result pre="States Background: Reproductive hormones impact the onset and course of" exact="multiple sclerosis" post="(MS). Recent interest in reproductive health in MS, as"/>
 <result pre="time. The rates of women limiting their pregnancy due to" exact="infertility" post="and lack of desire to have children remained stable,"/>
 <result pre="practices and disease course. P852 The role of breastfeeding in" exact="multiple sclerosis" post="patients S Perez-Sanchez 1, S Eichau-Madueño 1, M Rus-Hidalgo"/>
 <result pre="type of feeding. Methods: We observed all pregnancies in relapsing-remitting" exact="multiple sclerosis" post="(RRMS) women at Virgen Macarena University Hospital from 2004"/>
 <result pre="P853 Examining the effectiveness of pregnancy counseling in women with" exact="multiple sclerosis" post="of childbearing potential LH Travis 1, K Clarke 1,"/>
 <result pre="in September. P854 Sexual dysfunctions in female patients with relapsing-remitting" exact="multiple sclerosis" post="K Zebenholzer 1, R Prohazka 1, S Salhofer-Polanyi 1,"/>
 <result pre="the 42 MS patients 35.7 % had any form of" exact="sexual dysfunction," post="with primary sexual dysfunction being the most common form"/>
 <result pre="35.7 % had any form of sexual dysfunction, with primary" exact="sexual dysfunction" post="being the most common form (40 %), and 33.3"/>
 <result pre="most common form (40 %), and 33.3 % having tertiary" exact="sexual dysfunction." post="Of the 31 headache patients 22.6 % had any"/>
 <result pre="the 31 headache patients 22.6 % had any form of" exact="sexual dysfunction," post="with primary and tertiary sexual dysfunctions being the most"/>
 <result pre="more often had a combination of primary, secondary and tertiary" exact="sexual dysfunction." post="Depression and the psychological and physical scale of the"/>
 <result pre="psychological and physical scale of the SF-36 correlated significantly with" exact="sexual dysfunction" post="in both groups. Conclusions: A considerable number of females"/>
 <result pre="P856 Progestin content of oral contraceptives and the risk of" exact="multiple sclerosis" post="AM Langer-Gould 1, K Hellwig 2, LH Chen 1,"/>
 <result pre="first patient is 49 year old woman with relapsing remitting" exact="multiple sclerosis" post="(RRMS) on NZB for 3 years and 6months who"/>
 <result pre="opportunistic brain infection caused by the John Cunningham virus (JCV)," exact="progressive multifocal leukoencephalopathy" post="(PML) occurs in immunecompromised states, including treatment of multiple"/>
 <result pre="multifocal leukoencephalopathy (PML) occurs in immunecompromised states, including treatment of" exact="multiple sclerosis" post="(MS) with natalizumab. We treated fifteen patients with MS,"/>
 <result pre="To present an all-surviving cohort of 15 patients with natalizumab-associated" exact="progressive multifocal leukoencephalopathy" post="(PML) in whom management strategies evolved to a core"/>
 <result pre="1University Hospital of Padova, Padova, Italy Background: Natalizumab-treated relapsing remitting" exact="multiple sclerosis" post="(RRMS) patients may face a high risk of progressive"/>
 <result pre="multiple sclerosis (RRMS) patients may face a high risk of" exact="progressive multifocal leukoencephalopathy" post="(PML). Actually, in RRMS patients treated for more then"/>
 <result pre="SAEs, 14 Herpes Zoster events, 2 malignancies (excluding non melanoma" exact="skin cancer," post="NMSC) and 5 NMSC were recorded on fingolimod, compared"/>
 <result pre="P861 Longitudinal serum JCV indexes in MS patients with natalizumab-associated" exact="progressive multifocal leukoencephalopathy" post="A Vennegoor 1, JA van Rossum 1, M Wattjes"/>
 <result pre="serum antibodies is a risk factor for the development of" exact="progressive multifocal leukoencephalopathy" post="(PML) in multiple sclerosis (MS) patients treated with natalizumab."/>
 <result pre="factor for the development of progressive multifocal leukoencephalopathy (PML) in" exact="multiple sclerosis" post="(MS) patients treated with natalizumab. We hypothesize that higher"/>
 <result pre="with clear recommendations on immunization against varicella. P863 Treatment of" exact="multiple sclerosis" post="patients after 24 Natalizumab doses: a prospective observational study:"/>
 <result pre="Italy Background: Natalizumab is the most effective drug for relapsing-remitting" exact="multiple sclerosis" post="(RR-MS) but could rarely be associated with progressive multifocal"/>
 <result pre="relapsing-remitting multiple sclerosis (RR-MS) but could rarely be associated with" exact="progressive multifocal leukoencephalopathy" post="(PML), whose risk increases after 24 natalizumab administrations. Objectives:"/>
 <result pre="after NTZ discontinuation. P865 Anti-JC virus antibodies in a Portuguese" exact="multiple sclerosis" post="cohort I Correia 1, IB Marques 1, S Batista"/>
 <result pre="used off-label in various autoimmune disorders including MS, NMO, and" exact="myasthenia gravis." post="Early stage clinical trials and several case series have"/>
 <result pre="States Background: Alemtuzumab is approved in &amp;gt;30 countries for relapsing-remitting" exact="multiple sclerosis" post="(RRMS). In 3 clinical trials, alemtuzumab demonstrated superior efficacy"/>
 <result pre="times weekly. Standardized incidence ratios (SIRs) were calculated to quantify" exact="cancer" post="risk in alemtuzumab-treated patients compared with a retrospective MS"/>
 <result pre="of autoimmune thyroid disorders. The other most common malignancies were" exact="breast cancer" post="(SIR 0.85; 95% CI 0.35-2.04), malignant melanoma (SIR 0.88;"/>
 <result pre="autoimmune thyroid disorders. The other most common malignancies were breast" exact="cancer" post="(SIR 0.85; 95% CI 0.35-2.04), malignant melanoma (SIR 0.88;"/>
 <result pre="of anti-JCV-antibodies serves as an established risk predictor for natalizumab-associated" exact="progressive multifocal leukoencephalopathy" post="(PML). More recently, the level of antibodies (index) as"/>
 <result pre="in the limelight as serious adverse event of some new" exact="multiple sclerosis" post="(MS) drugs such as Natalizumab, Fingolimod, and Dimethyl Fumarate."/>
 <result pre="(WM) disease, since several &quot;cortical&quot; signs as seizures, behavioural disturbances," exact="aphasia" post="and cortical blindness have been described. The involvement of"/>
 <result pre="since several &quot;cortical&quot; signs as seizures, behavioural disturbances, aphasia and" exact="cortical blindness" post="have been described. The involvement of GM has been"/>
 <result pre="1 with HIV-related leukoencephalopathy, 3 MS subjects, 2 patients with" exact="metachromatic leukodystrophy" post="and 5 healthy controls were recruited in the study."/>
 <result pre="with HIV-related leukoencephalopathy, 3 MS subjects, 2 patients with metachromatic" exact="leukodystrophy" post="and 5 healthy controls were recruited in the study."/>
 <result pre="to the pial surface, were observed. In HIV-related leukoencephalopathy and" exact="metachromatic leukodystrophy" post="lesions were limited to the WM and never entered"/>
 <result pre="the pial surface, were observed. In HIV-related leukoencephalopathy and metachromatic" exact="leukodystrophy" post="lesions were limited to the WM and never entered"/>
 <result pre="P872 Application of serum natalizumab levels during plasma exchange in" exact="multiple sclerosis" post="patients with progressive multifocal leukoencephalopathy A Vennegoor 1, T"/>
 <result pre="natalizumab levels during plasma exchange in multiple sclerosis patients with" exact="progressive multifocal leukoencephalopathy" post="A Vennegoor 1, T Rispens 2, BW van Oosten"/>
 <result pre="PLEX may optimize the current treatment strategy. Methods: In four" exact="multiple sclerosis" post="(MS) patients who developed natalizumab-associated PML we measured serum"/>
 <result pre="first oral therapy approved for the treatment of relapsing remitting" exact="multiple sclerosis" post="(RRMS). Its therapeutic effect in MS is exerted through"/>
 <result pre="Results: A 49-yrs woman with history of mild, non-treatment requiring" exact="asthma" post="during adolescence was diagnosed with RRMS in 1999. She"/>
 <result pre="not contribute to reduced bone mineral density in patients with" exact="multiple sclerosis" post="A Olsson 1, D Oturai 1, PS Sorensen 1,"/>
 <result pre="in MS patients. Results: Osteopenia was present in 38% and" exact="osteoporosis" post="in 7% of the study population. The mean Z-score"/>
 <result pre="appears not to be the primary underlying cause of secondary" exact="osteoporosis" post="in MS patients. The principal factors associated with reduced"/>
 <result pre="Two-years clinical and radiological activity during fingolimod post-natalizumab in relapsing-remitting" exact="multiple sclerosis." post="Single-center experience R Hernández-Clares 1,2, E Carreón-Guarnizo 1,2, E"/>
 <result pre="(NTZ) was the treatment of choice in patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS) who had not responded after a course of"/>
 <result pre="aggressive onset of disease. In some patients, the risk of" exact="progressive multifocal leukoencephalopathy" post="(PML) causes NTZ withdrawal despite its efficacy. Fingolimod was"/>
 <result pre="While natalizumab therapy is highly efficacious for the treatment of" exact="multiple sclerosis" post="(MS), it does carry significant risk for progressive multifocal"/>
 <result pre="of multiple sclerosis (MS), it does carry significant risk for" exact="progressive multifocal leukoencephalopathy" post="(PML) in patients who have an immunosuppressant history, &amp;gt;=24"/>
 <result pre="(JCV) seropositivity is a risk factor for the development of" exact="progressive multifocal leukoencephalopathy" post="(PML) during natalizumab treatment in multiple sclerosis (MS) patients."/>
 <result pre="development of progressive multifocal leukoencephalopathy (PML) during natalizumab treatment in" exact="multiple sclerosis" post="(MS) patients. It has been suggested that patients who"/>
 <result pre="of NAT. P880 Management of infusion-associated reactions in alemtuzumab-treated relapsing-remitting" exact="multiple sclerosis" post="patients L Mayer 1, L Casady 2, G Clayton"/>
 <result pre="is approved in over 30 countries for treatment of relapsing-remitting" exact="multiple sclerosis" post="(RRMS). Alemtuzumab demonstrated superior efficacy over subcutaneous interferon beta-1a"/>
 <result pre="JCV antibody index and adhesion molecule expression levels in natalizumab-treated" exact="multiple sclerosis" post="patients - a cross-sectional study P Wipfler 1, A"/>
 <result pre="of anti-JC virus (JCV) antibodies is a risk factor for" exact="progressive multifocal leukoencephalopathy" post="(PML) development in natalizumab (NTZ)-treated multiple sclerosis (MS) patients."/>
 <result pre="factor for progressive multifocal leukoencephalopathy (PML) development in natalizumab (NTZ)-treated" exact="multiple sclerosis" post="(MS) patients. According to recent studies JCV reactivation occurs"/>
 <result pre="JC V serostatus. P882 Anti JC virus antibodies in pediatric" exact="multiple sclerosis" post="P Huppke 1, H Hummel 1, D Ellenberger 2,"/>
 <result pre="shown to be a very effective treatment in severe pediatric" exact="multiple sclerosis." post="So far no cases of progressive multifocal leukoencephalopathy have"/>
 <result pre="in severe pediatric multiple sclerosis. So far no cases of" exact="progressive multifocal leukoencephalopathy" post="have been reported in multiple sclerosis patients in this"/>
 <result pre="no cases of progressive multifocal leukoencephalopathy have been reported in" exact="multiple sclerosis" post="patients in this age group. Prevalence for anti JC"/>
 <result pre="antibody status on the clinical course in a large pediatric" exact="multiple sclerosis" post="cohort. Methods: Anti-JC virus antibodies were analyzed in serum"/>
 <result pre="course, NTZ is unfortunately associated with a risk of developing" exact="progressive multifocal leukoencephalopathy" post="(PML) that led to restriction use depending of PML"/>
 <result pre="allowed physicians to refine his decision. P884 Disease reactivation in" exact="multiple sclerosis" post="pregnant women who stopped natalizumab during the first gestational"/>
 <result pre="patients. Neurological irAES have been reported as single cases of" exact="aseptic meningitis," post="Guillain-Barré syndrome, facial palsy, myasthenia gravis, and Tolosa-Hunt syndrome."/>
 <result pre="as single cases of aseptic meningitis, Guillain-Barré syndrome, facial palsy," exact="myasthenia gravis," post="and Tolosa-Hunt syndrome. Objectives: This is the first case"/>
 <result pre="and Tolosa-Hunt syndrome. Objectives: This is the first case of" exact="multiple sclerosis" post="as irAE after IPI treatment. Methods: A 30-year-old patient"/>
 <result pre="Results: Brain biopsy ruled out cerebral metastases, but detected a" exact="multiple sclerosis" post="lesion with histopathological pattern I according to Lucchinetti et"/>
 <result pre="pattern I according to Lucchinetti et al. One month later" exact="optic neuritis" post="occurred as a first clinical manifestation and the diagnosis"/>
 <result pre="Background: John Cunningham virus (JCV) is known to cause rare" exact="progressive multifocal leukoencephalopathy" post="(PML) in natalizumab-treated MS-patients. Measuring of Anti-JCV Antibodies by"/>
 <result pre="patients (107 female, 36 male) at the outpatient clinic for" exact="multiple sclerosis" post="in Innsbruck, Austria have been tested for Anti-JCV Antibodies."/>
 <result pre="the test could be increased. P887 Is there an increased" exact="cancer" post="risk in people with relapsing multiple sclerosis taking cladribine?"/>
 <result pre="Is there an increased cancer risk in people with relapsing" exact="multiple sclerosis" post="taking cladribine? J Pakpoor 1, G Disanto 2, DR"/>
 <result pre="trial (CLARITY) of oral cladribine (Movectro) in people with relapsing" exact="multiple sclerosis" post="(pwRMS) reported significant efficacy. However, concerns over the safety"/>
 <result pre="by American and European regulatory bodies. Specifically, a suspected increased" exact="cancer" post="risk was key for the rejection of cladribine for"/>
 <result pre="Medicines Agency (EMA) in 2011. The small number of observed" exact="cancer" post="during CLARITY may be insufficient to definitively assess cancer"/>
 <result pre="observed cancer during CLARITY may be insufficient to definitively assess" exact="cancer" post="risk. Objectives: We compared the cancer risk of cladribine"/>
 <result pre="insufficient to definitively assess cancer risk. Objectives: We compared the" exact="cancer" post="risk of cladribine in CLARITY with other disease-modifying therapies"/>
 <result pre="pwRMS were included. Fisher’s exact test was used to compare" exact="cancer" post="rates. Results: Twelve phase III trials reported cancer rates"/>
 <result pre="to compare cancer rates. Results: Twelve phase III trials reported" exact="cancer" post="rates and were therefore included in this meta-analysis. Study"/>
 <result pre="interferon-beta 1a (IFN beta-1a)) were initially used for analysis. The" exact="cancer" post="rate in the CLARITY treatment group (1.13%) was not"/>
 <result pre="those with an IFN beta-1a comparator arm (1.05%, p=0.0951). No" exact="cancer" post="was detected in pwRMS assigned to placebo in CLARITY"/>
 <result pre="in pwRMS assigned to placebo in CLARITY whilst the combined" exact="cancer" post="rate of all other placebo groups was 1.19% (p=0.0159)."/>
 <result pre="rate of all other placebo groups was 1.19% (p=0.0159). The" exact="cancer" post="rate of zero in the CLARITY placebo group is"/>
 <result pre="demyelination (ORACLE), p=0.0012. In contrast, no difference was detected between" exact="cancer" post="rates in the treatment groups of CLARITY and ORACLE"/>
 <result pre="in CLARITY and ORACLE does not increase the risk of" exact="cancer" post="in pwRMS. The impression that it would appears driven"/>
 <result pre="impression that it would appears driven by an unusually low" exact="cancer" post="rate in the placebo group of CLARITY. Long term"/>
 <result pre="group of CLARITY. Long term follow-up will help determine the" exact="cancer" post="risk of all DMTs. Given its efficacy, tolerability and"/>
 <result pre="related to stem cells immune regulatory function in experimental autoimmune" exact="encephalomyelitis" post="(EAE) M Swiderek-Matysiak 1, M Fortak-Michalska 1, M Mycko"/>
 <result pre="with different immune regulatory potential assessed in animal model of" exact="multiple sclerosis," post="EAE. Methods: MicroRNA expression profile from freshly isolated BMSC"/>
 <result pre="stem cells used in a phase I clinical trial in" exact="multiple sclerosis" post="SM Planchon 1, I Warshawsky 2, JS Reese 3,4,"/>
 <result pre="I study of autologous mesenchymal stem cell (MSC) transplantation in" exact="multiple sclerosis" post="(MS), human MSCs were culture-expanded ex-vivo and infused IV."/>
 <result pre="increased probe coverage of genes relevant to stem cell and" exact="cancer" post="biology. Results: Some deletions and amplifications were detected in"/>
 <result pre="those that aim to improve the remyelination process in progressive" exact="multiple sclerosis," post="could be complimentary in targeting astrocytes, microglia, and infiltrated"/>
 <result pre="trial of autologous culture-expanded mesenchymal stem cell transplantation for relapsing" exact="multiple sclerosis" post="A Bar-Or 1, M-N Boivin 1, A Rozenberg 1,"/>
 <result pre="autologous MSCs administered intravenously in patients with relapsing forms of" exact="multiple sclerosis" post="(MS). Methods: In a single-arm open-label Phase I trial"/>
 <result pre="neural stem cells after therapeutic intrathecal transplantation in experimental autoimmune" exact="encephalomyelitis" post="A Merlini 1, D De Feo 1, F Ruffini"/>
 <result pre="neural stem/precursor cells (NPCs) ameliorates disease severity in experimental autoimmune" exact="encephalomyelitis" post="(EAE), the animal model of multiple sclerosis. Understanding the"/>
 <result pre="severity in experimental autoimmune encephalomyelitis (EAE), the animal model of" exact="multiple sclerosis." post="Understanding the kinetics of NPC behavior in vivo might"/>
 <result pre="experience in autologous hematopoietic stem cell transplantation in refractory aggressive" exact="multiple sclerosis" post="C Alcalá 1, F Pérez-Miralles 1, I Boscá 1,"/>
 <result pre="clinical experience of a series of refractory patients with aggressive" exact="multiple sclerosis" post="subject in which a BMT was performed at some"/>
 <result pre="BMT, 2 of them serious; 3 patients developed neoplasms (1" exact="carcinoma in situ" post="of the cervix, 2 breast cancers), with median time"/>
 <result pre="vitro and in the animal model of MS, experimental autoimmune" exact="encephalomyelitis" post="(EAE). Methods: Eight MS patients were selected with no"/>
 <result pre="outcome. P898 Autologous hematopoietic stem cell transplant in patients with" exact="neuromyelitis optica" post="J Burton 1, J Storek 2, P Duggan 2,"/>
 <result pre="and baseline EDSS 4.0. Transplant complications included transient asymptomatic febrile" exact="neutropenia" post="and volume overload. Her ARR 36 months post-transplant is"/>
 <result pre="P899 Generation and characterization of neuralized mesenchymal stem cells from" exact="multiple sclerosis" post="patients I Kassis 1, P Petrou 1, D Karussis"/>
 <result pre="Objectives: To generate and characterize neuralized mesenchymal stem cells from" exact="multiple sclerosis" post="patients. Methods: MSC were isolated from the BM of"/>
 <result pre="(NeuroCult™ NS-A).The immunomdualtory effects of MSC-NPs were tested with lymphocytes" exact="suppression" post="assay in vitro. Results: We were able to generate"/>
 <result pre="(GFAP marker) and oligodendrocytes (CNPase marker). Morevover, MSC-NPs induced dose-dependent" exact="suppression" post="of lymphocytes. Conclusions: The generation of MSC-NPs (which hold"/>
 <result pre="for neuroregeneration and remyelination in future autologous cell-therapy treatments for" exact="multiple sclerosis." post="P900 Anti-neural precursor cell (NPCs) - immune response in"/>
 <result pre="Anti-neural precursor cell (NPCs) - immune response in experimental autoimmune" exact="encephalomyelitis" post="(EAE) E Kesidou 1, O Touloumi 1, R Lagoudaki"/>
 <result pre="therapeutic safety in a recently completed Phase I trial in" exact="multiple sclerosis." post="As in our trial, standard ex-vivo culture techniques utilize"/>
 <result pre="use. P902 Assessment of bone marrow-derived cell therapy in progressive" exact="multiple sclerosis" post="(ACTiMuS) CM Rice 1, DI Marks 2, Y Ben-Shlomo"/>
 <result pre="immunological monitoring of autologous IL-10 modified dendritic cells transplantation in" exact="multiple sclerosis" post="G Bisaga 1, V Chirsky 1, M Odinak 1,"/>
 <result pre="Multiple sclerosis (MS) is postulated to be a T cell-mediated" exact="autoimmune disease" post="with altered antigen presentation. Dendritic cells (DCs) are the"/>
 <result pre="Symptom management P904 Cingulum bundle alterations underlie subjective fatigue in" exact="multiple sclerosis" post="M Pardini 1,2,3, L Bonzano 1,2, M Bergamino 1,2,"/>
 <result pre="Long-term, sustained safety and efficacy of repeat onabotulinumtoxinA treatment in" exact="multiple sclerosis" post="patients with neurogenic detrusor overactivity J Panicker 1, P"/>
 <result pre="300U were comparable. Most common AEs (onabotA 200U) were uncomplicated" exact="urinary tract infection" post="(58.3, 47.4, 47.6, 40.2, and 34.4%; cycles 1-5, respectively)"/>
 <result pre="fampridine enhances physical activity during everyday life in patients with" exact="multiple sclerosis" post="(FAMPKIN) D Weller 1, T Sutter 1, B Zörner"/>
 <result pre="effects on walking ability in a subset of patients with" exact="multiple sclerosis" post="(MS). Not only walking speed (Goodman and colleagues), but"/>
 <result pre="of fampridine-induced modifications of the gait pattern in patients with" exact="multiple sclerosis" post="L Lörincz 1, B Zörner 1, D Weller 1,"/>
 <result pre="1University Hospital Zurich, Department of Neurology, Zurich, Switzerland Background: Although" exact="multiple sclerosis" post="(MS) often leads to an impairment of ambulatory function,"/>
 <result pre="features of patients presenting with seizures at the time of" exact="multiple sclerosis" post="diagnosis: a 12-year retrospective case-control study A Jammoul 1,"/>
 <result pre="NJ, United States Background: Elevated body temperature in people with" exact="multiple sclerosis" post="(MS) relative to healthy individuals was recently reported for"/>
 <result pre="effects of prolonged-release fampridine on walking function in patients with" exact="multiple sclerosis" post="(FAMPKIN) B Zörner 1, K Reuter 1, L Filli"/>
 <result pre="(4-aminopyridine) on gait velocity in a subset of patients with" exact="multiple sclerosis" post="(MS). Fampridine blocks voltage-gated potassium channels leading to enhanced"/>
 <result pre="Restless legs syndrome, sleep quality and depression in relapsing remitting" exact="multiple sclerosis" post="and correlations with cervical spinal cord damage O Kilinc"/>
 <result pre="Faculty, Istanbul, Turkey Background: There is a growing interest in" exact="restless legs syndrome" post="(RLS) and sleep disorders in multiple sclerosis (MS). Spinal"/>
 <result pre="interest in restless legs syndrome (RLS) and sleep disorders in" exact="multiple sclerosis" post="(MS). Spinal cord (SC) damage represents a significant risk"/>
 <result pre="prevalence of RLS and depression in patients with relapsing remitting" exact="multiple sclerosis" post="(RRMS). Methods: A total of 93 RRMS patients (67"/>
 <result pre="in MS is required. P914 Reassessment of Lhermitte’s sign in" exact="multiple sclerosis" post="Y Beckmann 1, S Özakbaş 2, NG Bülbül 1,"/>
 <result pre="Background: The reliability and diagnostic value of Lhermitte’s sign in" exact="multiple sclerosis" post="(MS) has not been fully established. Objectives: The purpose"/>
 <result pre="with neuroradiologic and neurophysiologic abnormalities. P915 Restless leg syndrome and" exact="multiple sclerosis" post="M Terzi 1, D Yazıcı 1, M Onar 1"/>
 <result pre="+ group (p&amp;lt; 0.05). For clinical involvement, the presence of" exact="optic neuritis," post="tetraparesis, paresthesia and tremor was significantly higher in MS-RLS"/>
 <result pre="of sleep and measures of fatigue, depression and cognition in" exact="multiple sclerosis" post="RA Sater 1, M Gudesblatt 2, K Kresa-Reahl 3,"/>
 <result pre="States, 4Hope Neurology, Knoxville, TN, United States Background: People with" exact="multiple sclerosis" post="(MS) report more difficulty with poor sleep, fatigue, sleepiness,"/>
 <result pre="sleep efficiency (SE), periodic limb movements of sleep (PLMS), and" exact="obstructive sleep apnea" post="(OSA) in MS patients. The inter-relationship between symptoms and"/>
 <result pre="efficiency (SE), periodic limb movements of sleep (PLMS), and obstructive" exact="sleep apnea" post="(OSA) in MS patients. The inter-relationship between symptoms and"/>
 <result pre="for intractable chronic pain and spasticity in conditions such as" exact="multiple sclerosis" post="(MS). Objectives: To describe nabilone use in the UK"/>
 <result pre="of fampridine (4-aminopyridine) on the manual functions of patients with" exact="multiple sclerosis" post="Z Savin 1, I Lejbkowicz 1,2, L Glass-Marmor 1,2,"/>
 <result pre="Obersteiner-Redlich zone of the trigeminal nerve in an exacerbation of" exact="multiple sclerosis" post="(MS) D Anbarasan 1, J Herbert 2, J Howard"/>
 <result pre="sample size. P921 Changes in functional impairment in persons with" exact="multiple sclerosis" post="treated with dalfampridine AC Lo 1,2,3, JA Ruiz 1,"/>
 <result pre="impact functional performance and quality of life in persons with" exact="multiple sclerosis" post="(pwMS). Although dalfampridine extended release (D-ER) has been available"/>
 <result pre="of pwMS. P922 Walking ability and balance in patients with" exact="multiple sclerosis" post="treated with prolonged-release fampridine: randomized, double-blind MOBILE study R"/>
 <result pre="United States Background: Walking impairment is a common disability in" exact="multiple sclerosis" post="(MS) and negatively impacts patients’ quality of life (QoL)."/>
 <result pre="stable dose. One patient died during the follow up from" exact="aspiration pneumonia" post="due to MS related generalized paralysis. One patient opted"/>
 <result pre="dose. One patient died during the follow up from aspiration" exact="pneumonia" post="due to MS related generalized paralysis. One patient opted"/>
 <result pre="and is associated with reduced quality of life (QoL) in" exact="multiple sclerosis" post="(MS). Prolonged-release (PR) fampridine tablet (dalfampridine extended release in"/>
 <result pre="in France. P925 Special challenges of neuro palliative care in" exact="multiple sclerosis" post="patients J Koehler 1, G Lindena 2, B Basedow-Rajwich"/>
 <result pre="Palliative care is a special challenge in the treatment of" exact="multiple sclerosis" post="patients and an unmet need at present. In contrast"/>
 <result pre="previous studies of our neuropalliative care (NPC) treated patients with" exact="multiple sclerosis" post="(MS) in our center (MSK) we could demonstrate strong"/>
 <result pre="handwriting recordings. Samples were shuffled and rated by a blinded" exact="movement disorder" post="expert. Dystonic features (including dystonic posturing, mirror movements, geste"/>
 <result pre="the importance of recognizing dystonia as part of the complex" exact="movement disorder" post="that represents MS tremor. The presence of dystonia points"/>
 <result pre="P927 Efficiency sulbutiamine for treatment of fatigue in patients with" exact="multiple sclerosis" post="Y Khyzhniak 1,2, T Kobus 2, O Mialovytska 2"/>
 <result pre="Increase the effectiveness of diagnosis and treatment of fatigue in" exact="multiple sclerosis." post="Methods: Twenty-two patients (8 male and 14 female), aged"/>
 <result pre="analysis revealed that the severity of fatigue in patients with" exact="multiple sclerosis" post="increases significantly with age. There was no significant relation"/>
 <result pre="control trial of a brief multidisciplinary consultation intervention for treating" exact="sexual dysfunction" post="in multiple sclerosis LC Schairer 1, H Quinn 1,"/>
 <result pre="a brief multidisciplinary consultation intervention for treating sexual dysfunction in" exact="multiple sclerosis" post="LC Schairer 1, H Quinn 1, S Flood 1,"/>
 <result pre="Center, Teaneck, NJ, United States Background: Sexual dysfunction (SD) in" exact="multiple sclerosis" post="(MS) patients is a common but often overlooked symptom."/>
 <result pre="intervention utilizing a consultation model for adults with MS and" exact="sexual dysfunction." post="Further, to test the hypothesis that the intervention group"/>
 <result pre="of voltage-gated potassium channels, on walking speed in patients with" exact="multiple sclerosis" post="(MS) was demonstrated previously in two Phase III trials."/>
 <result pre="the 6-minute walk test (6mWT) assessing endurance, and the 12-item" exact="multiple sclerosis" post="walking scale (12MSWS) assessing the patients’ perspective. Results: Gait"/>
 <result pre="United States Background: Higher body temperature in persons with relapsing-remitting" exact="multiple sclerosis" post="(RRMS) relative to secondary progressive MS (SPMS) was recently"/>
 <result pre="a patient with residual cognitive sequelae after post-malaria acute demyelinating" exact="encephalomyelitis" post="(ADEM) LY Cheng 1, TI de Silva 2, ST"/>
 <result pre="report a case of severe ADEM two months after a" exact="malaria" post="infection, resulting in significant cognitive sequelae. We review the"/>
 <result pre="old man, who was diagnosed and treated for P. falciparum" exact="malaria" post="infection two months previously, presented with ataxia and confusion."/>
 <result pre="matter with Gadolinium enhancement. A diagnosis of post-infective acute demyelinating" exact="encephalomyelitis" post="(ADEM) was made and he was treated with intravenous"/>
 <result pre="Union (EU) for the improvement of walking in patients with" exact="multiple sclerosis" post="(MS). Objectives: In this study, we provide a descriptive"/>
 <result pre="Background: Spasticity is a frequent disabling symptom in patients with" exact="multiple sclerosis" post="(MS). Intrathecal baclofen (ITB) delivered by programmable pump devices"/>
 <result pre="T et al. Long-term effects of dalfampridine in patients with" exact="multiple sclerosis." post="J Neurol Sci 2014; 337:18-24. P935 PR-Fampridine improves walking"/>
 <result pre="on its impact on overall quality of life (QOL) in" exact="multiple sclerosis" post="(MS) is limited. Furthermore, qualitative studies indicate that spasticity"/>
 <result pre="influence overall QOL. P937 Radiosurgical thalamotomy for treatment of severe" exact="multiple sclerosis" post="associated tremor and its impact on quality of life"/>
 <result pre="Clinic, Mexico, Mexico, 3INNNMVS, Radiosurgery, Mexico, Mexico Background: Patients with" exact="multiple sclerosis" post="(MS) frequently suffer from disabling tremor. Pharmacological treatment has"/>
 <result pre="stimulation and thalamotomy diminish tremor in patients with parkinsonian or" exact="essential tremor." post="These represent a novel option, but the procedures can"/>
 <result pre="MS-induced tremor. Methods: We studied 4 patients with secondary progressive" exact="multiple sclerosis." post="All of them presented important tremor that significantly affected"/>
 <result pre="P938 Impact of bladder symptoms on quality of life in" exact="multiple sclerosis" post="K Abdel-Aziz 1, C Young 2, AJ Thompson 1,3,"/>
 <result pre="Kingdom Background: Neurogenic bladder dysfunction is a common feature of" exact="multiple sclerosis" post="(MS) but the effect of bladder dysfunction on quality"/>
 <result pre="treatment with prolonged-release fampridine on cognitive functioning in patients with" exact="multiple sclerosis" post="SD Broicher 1, O Geisseler 1, N Germann 1,"/>
 <result pre="prevent the long-term decline of cognitive functions in subjects with" exact="multiple sclerosis" post="(MS). In FAMPKIN, the original study of the EXTENSION"/>
 <result pre="formulation improves subjective spasticity and pain in patients with progressive" exact="multiple sclerosis" post="G van Amerongen 1, T Beumer 2, J Killestein"/>
 <result pre="using a diary. P943 Heterogeneous etiology of fatigue syndrome in" exact="multiple sclerosis" post="patients A Podlecka-Piętowska 1, S Szuwarska 1, M Nojszewska"/>
 <result pre="is one of the most common and disabling symptoms in" exact="multiple sclerosis" post="(MS). It can profoundly disrupt the occupational and social"/>
 <result pre="detrusor overactivity (NDO) is common in patients who suffer from" exact="multiple sclerosis" post="(ME). We assessed the efficacy, safety and effects on"/>
 <result pre="life of abobotulinumtoxinA (ABX-A) in patients with NDO resulting from" exact="multiple sclerosis." post="Objectives: Assess the efficacy, safety and effects on quality"/>
 <result pre="life of abobotulinumtoxinA (ABX-A) in patients with NDO resulting from" exact="multiple sclerosis." post="Methods: Twelve patients with MS underwent their first ABX-A"/>
 <result pre="A injections for refractory neurogenic detrusor overactivity in patients with" exact="multiple sclerosis" post="have a consistente effect on bladder control, resulting in"/>
 <result pre="in sustained improvement in quality of life. P945 Incidence of" exact="hypogonadism" post="and fatigue in male multiple sclerosis patients JJ Marriott"/>
 <result pre="of life. P945 Incidence of hypogonadism and fatigue in male" exact="multiple sclerosis" post="patients JJ Marriott 1, N Hall 1, N Reider"/>
 <result pre="or any other demographic or clinical features of MS. If" exact="hypogonadism" post="is common in MS this might reflect an unappreciated"/>
 <result pre="a neuroendocrine manifestation of MS itself. P946 Urinary dysfunction in" exact="multiple sclerosis;" post="frequency, characteristics and management in standard care L Wdowiak"/>
 <result pre="or nociceptive pain. Once considered rare, central pain syndromes in" exact="multiple sclerosis" post="(MS) are now recognized as highly prevalent and clinically"/>
 <result pre="including dysesthetic limb pain, L’hermitte’s sign, painful tonic spasms, and" exact="trigeminal neuralgia." post="It is widely acknowledged that pain has a significant"/>
 <result pre="pain in the MS population. P948 Increased arrhythmic incidence in" exact="multiple sclerosis" post="is associated with the location of the demyelinating plaques"/>
 <result pre="patients (20,37%) had abnormal holter with 8 (7,4%) patients having" exact="atrioventricular block" post="and 14 (12,96%) had CVA. Premature ventricular beats were"/>
 <result pre="implicated in the pathogenesis of numerous autoimmune diseases, including relapsing-remitting" exact="multiple sclerosis" post="(RRMS). Daclizumab HYP (DAC HYP) is a humanized monoclonal"/>
 <result pre="P952 Fingolimod promotes regulatory phenotype and function in B-cells of" exact="multiple sclerosis" post="patients B Grützke 1, S Hucke 1, CC Gross"/>
 <result pre="Düsseldorf, Germany Background: Fingolimod is a recently approved treatment for" exact="multiple sclerosis," post="a chronic inflammatory disease of the CNS, aimed at"/>
 <result pre="The influence of Fingolimod treatment on B cell subsets of" exact="multiple sclerosis" post="patients and its potential clinical relevance have not been"/>
 <result pre="of B cells derived from peripheral blood mononuclear cells from" exact="multiple sclerosis" post="patients under Fingolimod treatment in comparison to untreated multiple"/>
 <result pre="multiple sclerosis patients under Fingolimod treatment in comparison to untreated" exact="multiple sclerosis" post="patients and healthy controls, by flow cytometry and ELISA."/>
 <result pre="+ CD5 +) was significantly increased when compared to treatment-naïve" exact="multiple sclerosis" post="patients and to healthy controls, and significantly more regulatory"/>
 <result pre="of Fingolimod in correction of impaired B cell functions in" exact="multiple sclerosis" post="by enhancing regulatory B cells. P953 Vitamin D3 administration"/>
 <result pre="randomized, placebo and active-controlled, multi-center trial in patients with relapsing-remitting" exact="multiple sclerosis" post="(RRMS), the number of gadolinium-enhancing (Gd+) lesions and annualized"/>
 <result pre="immunomodulator, is currently under investigation for the treatment of relapsing-remitting" exact="multiple sclerosis" post="(MS). In previous clinical trials laquinimod considerably reduced the"/>
 <result pre="Republic Background: Alemtuzumab, a highly effective treatment in relapsing remitting" exact="multiple sclerosis" post="(RRMS), is associated with a long-standing lymphopenia, particularly of"/>
 <result pre="selectively affect antigen-presenting cells ex vivo and in vitro in" exact="multiple sclerosis" post="K Thomas 1, U Hainke 1, T Sehr 1,"/>
 <result pre="of innate immunity and suggested to be directly involved in" exact="multiple sclerosis" post="(MS) pathogenesis. The most frequent proinflammatory human blood DC"/>
 <result pre="subjects dosed with XP23829, a novel fumaric acid ester for" exact="multiple sclerosis" post="L Steinman 1, RJ Fox 2, D Lissin 3,"/>
 <result pre="Background: Teriflunomide is a once-daily oral immunomodulator approved for relapsing-remitting" exact="multiple sclerosis" post="(MS). It inhibits dihydroorotate dehydrogenase, the key mitochondrial enzyme"/>
 <result pre="various teriflunomide concentrations; teriflunomide impact in a rat experimental autoimmune" exact="encephalomyelitis" post="(EAE) model (disease severity, central nervous system [CNS] immune"/>
 <result pre="adenovirus. Teriflunomide-treated patients with MS mounted effective memory responses to" exact="influenza" post="vaccine (TERIVA, NCT01403376), and teriflunomide-dosed healthy subjects made seroprotective"/>
 <result pre="NCT01403376), and teriflunomide-dosed healthy subjects made seroprotective antibody responses to" exact="rabies" post="vaccine (neoantigen), albeit at lower titers than those given"/>
 <result pre="immunity in patients with MS. P960 Enhanced axonal metabolism in" exact="multiple sclerosis" post="patients treated with natalizumab OT Wiebenga 1,2, AM Klauser"/>
 <result pre="Background: The anti-inflammatory effect of natalizumab, second-line therapy for relapsing-remitting" exact="multiple sclerosis" post="(RRMS) in most countries, leads to a dramatic reduction"/>
 <result pre="levels of IL-2Rβγ and are expanded in DAC HYP-treated relapsing-remitting" exact="multiple sclerosis" post="(RRMS) patients. It is hypothesized that the increased numbers"/>
 <result pre="system and is in Phase 3 clinical trials for relapsing-remitting" exact="multiple sclerosis." post="Laquinimod crosses the blood-brain barrier and enters the CNS,"/>
 <result pre="receptor (TCR) repertoire in peripheral venous blood of patients with" exact="multiple sclerosis" post="(MS). Methods: The TCR repertoire of CD4+ and CD8+"/>
 <result pre="NY, United States Background: The primary innate immune cells in" exact="multiple sclerosis" post="(MS) consist of infiltrating macrophages/monocytes and resident microglia for"/>
 <result pre="treatment alters transcripts of susceptibility genes in peripheral blood of" exact="multiple sclerosis" post="patients H Faber 1, S Nischwitz 1, M Knop"/>
 <result pre="To date, more than 100 genetic risk loci associated with" exact="multiple sclerosis" post="(MS) have been detected in two recent genome-wide association"/>
 <result pre="emerging drug therapies in immune disorders and neurodegenerative diseases. In" exact="multiple sclerosis" post="(MS), miRNAs are abnormally expressed in cells comprising the"/>
 <result pre="P968 Effect of natalizumab treatment on circulating CD4+CD62L+ T-cells in" exact="multiple sclerosis" post="patients M Spadaro 1, F Marnetto 1, M Caldano"/>
 <result pre="of CD62L on CD4 + T-cells and the development of" exact="progressive multifocal leukoencephalopathy" post="(PML) in Natalizumab(NTZ)-treated Multiple Sclerosis (MS) patients. Objectives: To"/>
 <result pre="expression of T-cell subsets in the blood of patients with" exact="multiple sclerosis" post="B Fitzner 1,2, M Hecker 1,2, D Koczan 2,"/>
 <result pre="is an oral disease-modifying agent approved for the treatment of" exact="multiple sclerosis" post="(MS). It is a sphingosine-1-phosphate receptor modulator that prevents"/>
 <result pre="the Central Nervous System and reduces inflammatory immune reaction in" exact="multiple sclerosis" post="(MS). Therapy with Natalizumab is highly effective in relapsing"/>
 <result pre="Background: B cells are implicated in the immune pathogenesis of" exact="multiple sclerosis" post="(MS) by secreting antibodies and cytokines as well as"/>
 <result pre="Treg and iNKT cells after treatment with Fingolimod in relapsing-remitting" exact="multiple sclerosis" post="patients D Ferraro 1, AM Simone 1, F Vitetta"/>
 <result pre="of IFNβ1a. P975 Natalizumab increases HLA-G expression in PDCs of" exact="multiple sclerosis" post="patients AC Dionete 1, AS Moraes 1, M Domingues"/>
 <result pre="Campinas, Brazil Background: Multiple sclerosis (MS) is the most common" exact="autoimmune disease" post="of the central nervous system (CNS). MS symptoms are"/>
 <result pre="cell subsets in the blood of patients with relapsing remitting" exact="multiple sclerosis" post="K Thomas 1, J Blankeburg 1, J Eisele 1,"/>
 <result pre="evaluate effects of alemtuzumab on different immune cell subtypes in" exact="multiple sclerosis" post="patients. Methods: Peripheral blood mononuclear cells from 12 relapsing-remitting"/>
 <result pre="sclerosis patients. Methods: Peripheral blood mononuclear cells from 12 relapsing-remitting" exact="multiple sclerosis" post="patients were drawn before and after alemtuzumab infusion including"/>
 <result pre="-5 agonist in clinical development for the treatment of relapsing-remitting" exact="multiple sclerosis." post="In vitro studies have shown that ceralifimod is slowly"/>
 <result pre="CD20, a B-cell surface antigen, used for treatment of non-Hodgkin’s" exact="lymphoma" post="and several autoimmune diseases, including demyelinating diseases of the"/>
 <result pre="mg (FTY) is an established oral drug for relapsing-remitting (RR)" exact="multiple sclerosis" post="(MS). FTY inhibits lymphocytes egress from lymph nodes, interrupting"/>
 <result pre="of FTY treatment efficacy. P980 A two-years follow-up study of" exact="multiple sclerosis" post="patients treated with interferon-beta: predictive value of NAbs at"/>
 <result pre="Background: Interferon beta (IFN-beta) is a first-line treatment of relapsing-remitting" exact="multiple sclerosis" post="(MS); although the clinical efficacy of this therapy has"/>
 <result pre="effect (CPE) assay using the encephalomyocarditis murine virus on human" exact="lung carcinoma" post="cell line (A549). The titres were calculated according to"/>
 <result pre="TRU. P981 Stress induced angioplasticity is protective in experimental autoimmune" exact="encephalomyelitis" post="V Katyshev 1, N Esen 1, S Katysheva 1,"/>
 <result pre="underlie the pathophysiology of a number of neurodegenerative diseases including" exact="multiple sclerosis" post="(MS). We hypothesize that treatment strategies that restore vascular"/>
 <result pre="clinical outcome in myelin oligodendrocyte glycoprotein (MOG) peptide-induced experimental autoimmune" exact="encephalomyelitis" post="(EAE). Objectives: Identify new molecular targets that promote repair"/>
 <result pre="new molecular targets that promote repair in neurodegenerative diseases including" exact="multiple sclerosis." post="EAE with stress induced angioplasticity is the key model"/>
</results>
